

Regeneration in the nervous system with erythropoietin

Kenneth Maiese¹

¹*Cellular and Molecular Signaling, Newark, New Jersey 07101*

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. The growth factor and cytokine erythropoietin
 - 3.1. Background of erythropoietin
 - 3.2. Expression of erythropoietin
 - 3.3. Structure and activity of erythropoietin
 - 3.4. Production of erythropoietin
4. Signaling pathways of erythropoietin
 - 4.1. Erythropoietin and protein kinase B (Akt)
 - 4.2. Erythropoietin, forkhead transcription factors, sirtuins, and Wnt signaling
 - 4.3. Erythropoietin and mTOR
5. Erythropoietin and programmed cell death
 - 5.1. Apoptosis
 - 5.2. Autophagy
6. Erythropoietin and clinical efficacy
7. Future considerations for erythropoietin
8. Acknowledgments
9. References

1. ABSTRACT

Globally, greater than 30 million individuals are afflicted with disorders of the nervous system accompanied by tens of thousands of new cases annually with limited, if any, treatment options. Erythropoietin (EPO) offers an exciting and novel therapeutic strategy to address both acute and chronic neurodegenerative disorders. EPO governs a number of critical protective and regenerative mechanisms that can impact apoptotic and autophagic programmed cell death pathways through protein kinase B (Akt), sirtuins, mammalian forkhead transcription factors, and wingless signaling. Translation of the cytoprotective pathways of EPO into clinically effective treatments for some neurodegenerative disorders has been promising, but additional work is necessary. In particular, development of new treatments with erythropoiesis-stimulating agents such as EPO brings several important challenges that involve detrimental vascular outcomes and tumorigenesis. Future work that can effectively and safely harness the complexity of the signaling pathways of EPO will be vital for the fruitful treatment of disorders of the nervous system.

2. INTRODUCTION

In the large developing nations that include India and China, the number of elderly individuals will increase from current levels of approximately 5 percent to

almost 10 percent over the next several decades. Aging of the population also is occurring at a significant rate in developed nations around the globe. In these nations, the number of individuals over the age of 65 has doubled during the prior 50 years (1). Life expectancy is increasing in these developed countries and is accompanied by a one percent decrease in the age-adjusted death rate from the years 2000 through 2011(2). Although improvements of healthcare and stable environments are important factors for the increased longevity of the world's population, a rise in chronic pathologic disorders has paralleled the aging of the world's population. According to the World Health Organization, more than 60 percent of the 57 million global deaths result from noncommunicable diseases (NCDs) and almost 80 percent of these NCDs occur in low and middle-income countries (3). In particular, a rise in the incidence of neurodegenerative disorders is expected to ensue (4,5). Acute and chronic neurodegenerative disorders lead to disability and death in more than 30 million individuals worldwide (6).

Chronic neurodegenerative disorders such as Alzheimer's disease (AD) can impact a large proportion of the global population (7). Although familial cases of AD represent less than 2 percent of all presentations (8), usually occur prior to age 55 (9), and represent an autosomal dominant form of a mutated amyloid precursor

protein (APP) gene as well as mutations in the presenilin 1 or 2 genes (10), 10 percent of the global population over the age of 65 are affected with sporadic AD. For disorders such as Parkinson's disease (PD), also a chronic progressive neurodegenerative disease (11,12), approximately 50,000 new cases present in the United States alone each year. It is estimated that 1 to 4 percent of individuals over 60 suffer from PD in the world and this number of affected individuals may double by the year 2030.

Acute neurodegenerative disorders also place a severe burden on the world's population (13,14). Cerebrovascular disease leads to multiple complications that affect both the livelihood and minimal daily function of an individual (15,16). Approximately 15 million individuals suffer from a stroke every year, one of the five leading causes of death (17). NCDs such as cardiovascular disease and diabetes can contribute to acute neurodegenerative disease that include stroke (18,19). In the United States, almost 800,000 strokes occur per year at an annual cost of 75 billion US dollars (13). Traumatic brain injury (TBI) also leads to neurological disability and death throughout the world (20,21). TBI can have a two-fold effect to result in acute injury to the nervous system as well as subsequent chronic impairment (22-24). In the United States, approximately 50,000 individuals die every year as a result of TBI and more than 100,000 individuals suffer with chronic disability (25). If severe trauma occurs, almost one half of these individuals will eventually die.

3. THE GROWTH FACTOR AND CYTOKINE ERYTHROPOIETIN

3.1. Background of erythropoietin

Both acute and chronic neurodegenerative disorders comprise a broad array of pathologies in the nervous system. As a result, numerous therapeutic strategies are under development for neurodegenerative disease. These include therapies directed against oxidative stress (20,24,26-34), exposure to metal toxicity (35-39), loss of sirtuin activity (4,7,40-48), poly(ADP-ribose) polymerase-1 (PARP-1) over-activation (49-59), decreased metabotropic glutamate activity (60-72), cellular metabolic dysfunction (19,28, 73-78), defects in gamma-aminobutyric acid (GABA) signaling (79-83), transcription factor activation (4,47, 80, 84-99), Src homology-2 (SH2) domain phosphorylation (100-107), components of the mechanistic target of rapamycin (mTOR) pathway (7,16, 108-120), and growth factors (119,121-125).

In the armamentarium of new agents under development, the cytokine and growth factor erythropoietin (EPO) offers exciting and new prospects for the treatment of neurodegenerative disorders. The *EPO* gene resides on chromosome 7, represents a single copy

in a 5.4. kb region of the genomic DNA, and encodes for a polypeptide chain that has initially 193 amino acids (126). Once generated as a protein, EPO is then processed and cleaved of a 27 amino acid hydrophobic secretory leader at the amino-terminal to result in a 166 amino acid peptide (127). A mature protein is subsequently formed with the removal of a carboxy-terminal arginine¹⁶⁶ in the mature human and recombinant human EPO (rhEPO) to generate a circulatory EPO protein of 165 amino acids with a molecular weight of 30.4. kDa (128-131) (Table 1).

The concept of circulatory and potentially protective proteins in the body actually predated the discovery of EPO. Ernest Sterling in 1905 introduced the term "hormones", a term with Greek origins meaning to "excite" or "arouse", to describe the action of agents that are blood borne to target distant organs of the body (132). Prior to this discussion, Arnold Adolphe Berthold described messenger signals that could communicate among the different bodily organs (133). In addition, Claude Bernard spoke about the internal secretion of chemicals in the body with the release of glucose from glycogen in the liver (129,134).

3.2. Expression of erythropoietin

EPO and its receptor (EPOR) are expressed in numerous tissues and initially it was presumed that EPO functioned only as a circulatory agent in the body. In 1906, Carnot and Deflandre performed studies to show that following a bleeding stimulus in rabbits, immature red blood cells in these animals would be produced (135). Carnot and Deflandre termed this agent as "hemopoietine". This work was repeated and confirmed by other investigators to observe reticulocytosis in bled animals (136-138).

The agent responsible for this reticulocytosis was later termed EPO. Human EPO protein was eventually purified. The gene for *EPO* was cloned and allowed for the development of recombinant EPO for clinical use (139,140). At present, erythropoiesis-stimulating agents (ESAs), which include EPO, are approved for the treatment of anemia that results from chronic kidney failure, human immunodeficiency virus, chemotherapy, and to reduce blood transfusions for surgery (141,142). The primary site for the production and secretion of EPO are the kidney peritubular interstitial cells (143). EPO also is present in other organs that include the brain, uterus, and liver (143-147).

During development, production of EPO and EPOR are modified (129). EPO production in gestation is increased, but later EPO is suppressed following birth to be regulated by the tissue oxygen supply. Although elevated expression of the EPOR is present in early embryonic neuronal tissues, EPOR expression is significantly reduced following the maturation of the brain. EPO secretion in the brain is more sustained than

Table 1. Regenerative and protective properties of EPO in the nervous system

Property	Function
EPO structure	The integrity of EPO, a 30.4. kDa protein, is dependent upon the structure and the maintenance of the oligosaccharide side chains The oligosaccharides and the glycosylated chains protect EPO from free radical oxygen degradation
EPO production	EPO expression is regulated by changes in oxygen tension HIF-1 modulates the expression of EPO and EPOR EPO production can be affected by other entities such as trophic factors, metabolic changes, infection, cytokines, selenium, and neuronal depolarizations
EPO signal transduction pathways	EPO phosphorylates and activates Akt to lead to cytoprotection, reduce inflammation, and prevent oxidative stress mediated injury EPO controls the nuclear translocation and the post-translational processing of FoxOs to prevent the induction of "pro-apoptotic proteins" EPO employs SIRT1 to maintain cellular energy homeostasis and control cellular differentiation EPO relies upon Wnt/WISP1 signaling to foster stem cell survival, block FoxO protein activity, prevent cellular injury during toxin exposure, and maintain the integrity of non-neuronal cells in the nervous system EPO relies upon mTOR for neuronal cell development, differentiation, and survival EPO controls mTOR and its down-stream signaling pathways that involve PRAS40 and AMPK to promote stem cell development, cell differentiation, and cell survival
EPO, apoptosis, and autophagy	EPO can prevent apoptotic injury during oxidative stress against multiple injuries such as advanced glycation end-product exposure, A β toxicity, and hypoxia EPO can block autophagy through the activation of mTOR. Under some conditions, EPO can suppress apoptotic cell injury through increased AMPK and autophagy activity
EPO clinical efficacy	EPO may provide neuroprotection against developmental impairment in preterm infants and offer cognitive improvement in elderly patients with myelodysplastic syndromes EPO may assist with protection against neurological impairment through improved cardiovascular function

Akt: protein kinase B; A β : beta-amyloid; AMPK: AMP activated protein kinase; EPO: erythropoietin; EPOR: erythropoietin receptor; FoxO: mammalian forkhead transcription factors of the O class; HIF-1: Hypoxia-inducible factor 1; mTOR: mechanistic target of rapamycin; PI 3-K: Phosphoinositide 3-kinase; PRAS40: the proline rich Akt substrate 40 kDa; SIRT1: silent mating type information regulation 2 homolog 1 (*S. cerevisiae*); WISP1: wnt1 inducible signaling pathway protein 1; Wnt: proteins derived from the *Drosophila Wingless (Wg)* and the mouse *Int-1* genes

in peripheral organs such as the kidney, suggesting that EPO production may originate in the brain and possibly crosses the blood-brain barrier to reach the blood and peripheral organs. Primary neurons and neuronal cell lines also are able to retain the capacity to express EPO in an oxygen-dependent manner (126,141).

3.3. Structure and activity of erythropoietin

The integrity of EPO is dependent upon the structure and the maintenance of the oligosaccharide side chains (147,148) (Table 1). EPO contains four glycosylated chains that include three *N*-linked and one *O*-linked acidic oligosaccharide side chains (149). The *N*-linked glycosylation sites occur at aspartyl²⁴, aspartyl³⁸, and aspartyl⁸³. The *O*-linked glycosylation site occurs at serine¹²⁶. The *N*- and *O*-linked chains may be required for the production and secretion of the mature EPO (148). The carbohydrates are important for the clearance of EPO, since EPO molecules with high sialic acid content can be easily cleared by the body through the liver (150).

The molecular structure of EPO also determines the biological activity of this protein. The oligosaccharides

in EPO have been reported to provide protection from free radical activity (151) and the carbohydrate chains of EPO stabilize the protein (152). The glycosylated chains also protect EPO from free radical oxygen degradation (149). In addition, reduction of the two disulfide bonds formed between cysteine⁷ and cysteine¹⁶⁰ and between cysteine²⁹ and cysteine³³ leads to the loss of activity of EPO. Alkylation of the sulfhydryl groups leads to irreversible loss of the activity of EPO. Re-oxidation of EPO after reduction by guanidine restores almost 85 percent of the biological activity of EPO (153).

3.4. Production of erythropoietin

Almost seven decades prior, EPO was correlated to depressed oxygen levels. In parabiotic rats when only one partner was exposed to hypoxia, EPO was demonstrated to increase hemoglobin levels (154). Prior to such studies, EPO levels were believed to be correlated with decreased red blood cell counts. However, EPO expression is now known to be regulated by changes in oxygen tension and not by the concentration of red blood cells (144,155,156) (Table 1). Hypoxia-inducible factor 1 (HIF-1) modulates the expression of EPO and the EPO receptor (EPOR) to increase the production

of EPO as required (126,144,157,158). Independently, HIF-1 is an agent that can promote cellular protection against injury (159-161). Once HIF-1 is activated, gene transcription of EPO and EPOR occurs and is controlled through the transcription enhancer region in the 3'-flanking region of the EPO gene that binds to HIF-1 (126,129).

EPO also is regulated through pathways that may not rely upon exposure to hypoxia (132). EPO in the amniotic fluid of patients with diabetes can be elevated (162). It is unclear if this suggests an attempt to repair tissue at risk for injury by EPO, but EPO blood levels are elevated and associated with greater disability during brain maturation exposed to a toxic environment (163). Insulin can stimulate EPO production in specific cells that include astrocytes (164). During chronic hyperglycemia in adults, EPO levels can become depressed (165). Agents that decrease inflammation in cerebral microglia have been demonstrated to lead to the release of EPO (166). Malaria can result in significant serum levels of EPO (167) and EPO serum concentrations are raised during xenon anesthesia in cardiac surgery (168). Depletion of selenium, an anti-oxidant, can lead to increased EPO expression (169). Cadmium exposure, raised intracellular calcium, and neuronal depolarizations can affect the expression of EPO (145,149,170). In addition, cytokines, including insulin-like growth factor (IGF), tumor necrosis factor- α (TNF- α) (171), interleukin-1b (IL-1b), and interleukin-6 (IL-6) can increase EPO and the EPOR expression (126,147,172).

4. SIGNALING PATHWAYS OF ERYTHROPOIETIN

4.1. Erythropoietin and protein kinase B (Akt)

EPO relies upon multiple signaling pathways that can lead to tissue repair and cellular protection. Phosphoinositide 3-kinase (PI 3-K) and protein kinase B (Akt) are principal pathways that offer cellular protection through EPO (Table 1). PI 3-K phosphorylates membrane lipids and regulates the transition of Akt from the cytosol to the plasma membrane (173). Akt is phosphorylated on the serine⁴⁷³ and threonine³⁰⁸ residues by phosphoinositide dependent kinase (PDK) PDK1 and PDK2 (103,174,175). Independently, Akt can lead to the protection of cells in the nervous system during estrogen signaling (176), activation of pro-apoptotic proteins (27,47, 62, 84, 86, 177-179), spinal muscular atrophy (180), protein phosphatase activity (181), β -amyloid (A β) toxicity (99,182-193), oxygen-glucose deprivation (194-198), hypoxia (109,199-202), and in models of diabetes mellitus (203-208).

EPO can phosphorylate Akt at serine⁴⁷³ to activate Akt (141,209-213). Through Akt, EPO can affect both the function and survival of cells. In endothelial cells, EPO improves the vasculogenic potential of peripheral blood mononuclear cells and promotes

adhesiveness of the cells through Akt activation (214). In regards to increased survival, EPO activates Akt to prevent oxidative stress and injury from free radicals (194,199,203,209-211,215,216), prevent A β toxicity in microglia and neurons (186,217-219), block vascular demise and reduce inflammation (194,199, 203, 204, 216, 220-226), and foster neuronal and non-neuronal cell survival (196,210,215,227-229).

4.2. Erythropoietin, forkhead transcription factors, sirtuins, and Wnt signaling

In addition to Akt, EPO controls the signaling pathways of mammalian forkhead transcription factors of the O class (FOXO), the silent mating type information regulation 2 homolog 1 (*S. cerevisiae*) (SIRT1), and Wnt proteins, derived from the *Drosophila Wingless* (*Wg*) and the mouse *Int-1* genes. Mammalian FOXO proteins include FOXO1, FOXO3, FOXO4, and FOXO6 (230). For the nomenclature of these proteins, all letters are capitalized for human Fox proteins. However, in the mouse, only the initial letter is listed as uppercase. In addition, for all other chordates the initial and subclass letters are in uppercase (93). Since they are transcription factors, FoxO proteins bind to DNA (231,232) to affect the transcription of proteins that usually are "pro-apoptotic" (233). Multiple processes control the activity of FoxO proteins (234). These can include the regulation of the translocation of FoxO proteins to the nucleus. For example, Akt activation leads to phosphorylation of FoxO proteins that will bind FoxO proteins to 14-3-3 proteins, prevent nuclear translocation, and block the transcription of target genes that promote apoptosis (47,169,194,235). In addition, other post-translation protein changes in FoxO proteins include acetylation (47,95,236), ubiquitylation (54,97,206,232), and phosphorylation (47, 86,99,178,194,204,207,236-240). Acetylation of FoxO proteins can increase the Akt mediated phosphorylation of these proteins (241) and inhibit ubiquitination (93). In neurons, FoxO3a activation and p27 (kip1) transcription can result in apoptosis (242). In microglial cells and neurons, knockdown of FoxO3a and blockade of FoxO3a translocation to the nucleus leads to the increased survival during oxidative stress (47,243). Phosphorylation of FoxO3a and the nuclear export of FoxO3a protects neurons (244) and endothelial cells in models of experimental diabetes mellitus (204,206,207,221). During stroke in animal models, FoxO3a interaction with cell cycle induction proteins may play a role in neuronal apoptotic cell death (95).

The sirtuin SIRT1 has a significant role in the control of FoxO proteins (4). As a histone deacetylase, SIRT1 reversibly deacetylates FoxO proteins (41) and can maintain cellular and tissue function during periods of starvation through pathways involving autophagy (245). Through the deacetylation of FoxOs, SIRT1 leads to increased cortical bone formation with osteoblast progenitors by blocking FoxO protein binding

to β -catenin that would inhibit Wnt signaling (246). SIRT1 and FoxO proteins may work synergistically to protect cells. Increased FoxO3a and SIRT1 activity with a reduction in autophagy limits oxidative stress in human bronchial epithelial cells exposed to cigarette smoke condensates (247). Loss of the forkhead transcription factors FoxO1 and FoxO3 in combination with decreased SIRT1 activity during oxidative stress leads to a reduction in autophagy and subsequent chondrocyte cell death, suggesting that SIRT1 with FoxO proteins may be required for cellular protection during oxidative stress (248).

Several studies also suggest that inhibition of FoxO protein activity that requires SIRT1 activity can increase cell survival. SIRT1 can increase lifespan in higher organisms and offer protection against oxidative stress in neuronal cells (249). SIRT1 activity can foster cell survival in the nervous system through the blockade of FoxO protein activity (41,250-253). During this protective process, promotion of SIRT1 nuclear translocation increases neuronal survival (47). If SIRT1 activity is lost, FoxO1 expression during high glucose exposure can lead to endothelial cell dysfunction (254). Of note, the amount of SIRT1 activity can be a critical modulator of cell survival. SIRT1, and in general sirtuins, play a significant role during vascular repair (207,255-257) and cardiovascular disease (4,258). Exercise training in rodents can limit age-related impairments through the increase in anti-oxidant pathways and the up-regulation of SIRT1 activity and FoxO3a expression (259). Yet, it appears that anti-oxidant activity such as through catalase expression and FoxO protein dependent pathways requires SIRT1 activity that increases less than 7.5-fold (260). Levels of SIRT1 activity that exceed 12.5-fold can result in apoptosis and cardiac dysfunction (260).

SIRT1 activity can be regulated by several pathways. FoxO proteins can control SIRT1 transcription and increase SIRT1 expression (261). Furthermore, apoptotic pathways associated with p38 (262) and c-Jun N-terminal kinase -1 (JNK1) (263) can reduce SIRT1 activity and increase caspase activity that can lead to the degradation of SIRT1 (264). Pathways that involve Wnt signaling can block the degradation of SIRT1, maintain its activity, and prevent caspase activation (27,47,265,266). Wnt proteins are cysteine-rich glycosylated proteins that are proliferative in nature and oversee vascular cell development (267-269), stem cell development (122,246,270-273), cellular turnover (274), immune function (251,275-277), tumor cell growth (236,271,278-281), and neuronal survival (156,275,282-284). In the brain, loss of Wnt signaling may be tied to cognitive decline (282), spinal cord injury (285,286), oxidative stress injury (47,197), long-term memory impairment (287), immune cell loss (243,277,288-290), neurodegenerative disorders (284,291,292), depression (293), and cerebral

ischemia (294-296). Wnt signaling protects against programmed cell death (183,297, 298) and uses β -catenin for the phosphorylation and inhibition of FoxO proteins such as FoxO3a during oxidative stress (239). In neurons, Wnt signaling activates Akt (183,197, 299,300), limits the deacytation of FoxO3a (47), and maintains FoxO3a in the cytoplasm to prevent the loss of mitochondrial membrane permeability, cytochrome c release, Bad phosphorylation, and activation of caspases (243). Wnt1 inducible signaling pathway protein 1 (WISP1/CCN4) is a target of Wnt1 signaling that regulates programmed cell death, extracellular matrix production, tumorigenesis, cellular migration, fibrosis, and mitosis (268,274,278, 301-303). Similar to Wnt1 signaling, WISP1 protects neurons through the phosphorylation of FoxO3a, by sequestering FoxO3a in the cytoplasm with protein 14-3 3, and by limiting deacytation of FoxO3a (47). WISP1 also promotes SIRT1 activity and trafficking to the cell nucleus (47). Conversely, FoxO proteins can block Wnt signaling. FoxO3a can bind to β -catenin and reduce the expression of β -catenin target genes (304). FoxO proteins also may antagonize Wnt signaling pathways during oxidative stress and aging to block the proliferation of osteoblast precursors (305).

For FoxO proteins, EPO controls the nuclear translocation and the post-translational processing of FoxOs to promote cellular survival (29) (Table 1). Through the activation of Akt, EPO can phosphorylate and inactivate FoxO proteins (306) such as FoxO3a (194,307-309). EPO can promote the binding of FoxO3a to 14-3-3 protein to sequester FoxO proteins in the cytoplasm of cells and prevent nuclear translocation and transcription of "pro-apoptotic" proteins (169,194,310). EPO promotes erythroid progenitor cell development that requires the modulation of FoxO3a activity (147,169,311). In addition to FoxO3a phosphorylation, EPO subsequently down-regulates the protein p27 (kip1) involved in inhibition of cell cycle regulation (237). EPO can protect brain endothelial cells during periods of oxygen-glucose deprivation by phosphorylating FoxO3a, inhibiting the activity of the protein, and blocking translocation to the nucleus (221,312). In models of cerebral ischemia, EPO limits activities of FoxO1 in addition to other pathways to reduce ischemic stroke size (313).

Closely linked with the neuroprotective capacity of EPO is SIRT1 and Wnt signaling (Table 1). In adipocytes, EPO increases metabolic activity and maintains adipose energy homeostasis to protect against the complications of metabolic disorders through the combined activation of peroxisome proliferator-activated receptor-alpha (PPAR α) and SIRT1 (314). In regards to cellular differentiation, EPO employs SIRT1 to modulate skeletal myogenic differentiation (315). In endothelial cells of the brain during oxygen-glucose exposure, EPO promotes the subcellular trafficking of SIRT1 to the nucleus which is necessary for EPO to foster vascular

protection and to prevent mitochondrial depolarization, cytochrome c release, Bad, and caspase activation (221).

EPO also relies upon Wnt signaling that can control FoxO proteins to provide cellular protection. EPO protects against elevated glucose exposure in vascular endothelial cells by maintaining the expression of Wnt1 signaling (316). EPO enhances Wnt signaling to maintain the survival of mesenchymal stem cells (317), block A β toxicity in cerebral microglia (186), and maintain microglial cell integrity during oxidative stress (227). In other vascular systems that involve renal tissue, EPO prevents renal tubular cell apoptosis through Wnt7b and β -catenin and by down-regulating specific micro-RNAs (miRNA) (318,319). EPO employs Wnt signaling to reduce the activity of FoxO proteins and increase cell survival (93,204). EPO uses Wnt1 to inhibit FoxO3a activity and maintain endothelial cell survival during elevated glucose (204).

4.3. Erythropoietin and mTOR

The pathways of Akt and Wnt signaling employed by EPO also intersect with the mechanistic target of rapamycin (mTOR). mTOR also is known as the mammalian target of rapamycin and FK506-binding protein 12-rapamycin complex-associated protein 1 (116,320). It is a 289-kDa serine/threonine protein kinase and is encoded by a single gene *FRAP1* (7,321,22). mTOR functions as a vital component in the protein complexes of mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) (116,323). mTORC1 contains Raptor (Regulatory-Associated Protein of mTOR), the proline rich Akt substrate 40 kDa (PRAS40), Deptor (DEP domain-containing mTOR interacting protein), and mammalian lethal with Sec13 protein 8 (mLST8). mTORC2 has some of the same components of mTORC1 that include Deptor and mLST8, but also contains Rictor (Rapamycin-Insensitive Companion of mTOR), the mammalian stress-activated protein kinase interacting protein (mSIN1), and the protein observed with Rictor-1 (Protor-1) (11,13).

The hamartin (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2) complex is an inhibitor of mTORC1 (6,323). Although multiple regulatory phosphorylation sites are known to exist for TSC1, control of the TSC1/TSC2 complex can be regulated through pathways that include Akt and AMP activated protein kinase (AMPK) that phosphorylate TSC2 (13,324,325). Akt phosphorylates TSC2 on multiple sites that destabilizes TSC2 and disrupts its interaction with TSC1. Importantly, a limited reduction in TSC2 activity has been demonstrated to be necessary for cellular protection against A β to allow for mTOR activation, since complete knockdown of TSC2 can limit cellular protection (187). AMPK also phosphorylates TSC2 to inhibit mTORC1 activity (19,326). In the nervous system, AMPK activation can limit A β production and secretion (327,328), reduce

oxidative stress parameters in diabetic animals with cognitive dysfunction (329), limit infarct size in models of stroke (330), be responsible for lifespan extension (331), may modulate neuroinflammation (332), and prevent memory impairment (193). Yet, AMPK activation is not consistently beneficial. The degree of AMPK activity is an important consideration, since in some experimental models involving cellular metabolism, AMPK activation promotes apoptotic cell death such as in pancreatic islet cells (333). In addition, excessive AMPK activation may lead to aberrant A β production (187,327) and neuronal injury (334,335). Pathways such as Wnt signaling can counteract the negative effects of AMPK. For example, WISP1 provides a minimal level of TSC2 and AMPK activity to control both cell survival and cell metabolism (187). WISP1 controls AMPK activation by differentially decreasing phosphorylation of TSC2 at Serine¹³⁸⁷, a target of AMPK, and increasing phosphorylation of TSC2 at Threonine¹⁴⁶², a target of Akt (187). The ability of WISP1 to modulate AMPK activity also is important for the control of cellular metabolism (326).

EPO relies upon mTOR for neuronal cell development, differentiation, and survival (16,76) (Table 1). EPO requires mTOR for the differentiation of neural precursor cells to achieve a neuronal phenotype (336) and for the protection of retinal progenitor cells from oxidative stress (337). In models of sepsis-induced encephalopathy, protection against cognitive loss by EPO is lost during inhibition of mTOR pathways (229). EPO controls mTOR and its down-stream signaling pathways that involve PRAS40 to increase neuronal survival during oxygen-glucose deprivation (310). EPO, through mTOR and Wnt signaling, maintains microglial survival during oxidative stress (227). EPO can block A β toxicity through Wnt signaling and mTOR pathways as well to prevent caspase activation and apoptosis (186). During hypoxia-reoxygenation stress, EPO increases mTOR activity to protect hippocampus-derived neuronal cells (338). In the mTOR pathway, AMPK also may impact the biological function of EPO. The ability of EPO to oversee neuroinflammation may be linked to AMPK activity (166). EPO also may require a specific level of activation of AMPK to alleviate detrimental effects of oxidative stress (339). Yet, the concentration and activity of EPO may influence the protective actions of mTOR and signaling pathways associated with AMPK. High concentrations of EPO may increase cellular damage and lessen the activity of mTOR (340).

5. ERYTHROPOIETIN AND PROGRAMMED CELL DEATH

5.1. Apoptosis

EPO can block apoptotic cell death through multiple pathways that involve Akt activation, promotion of Wnt signaling, SIRT1 activity, modulation of the mTOR pathway, and inhibition of FoxO

protein nuclear translocation and transcription. Apoptosis has an early phase that involves the loss of plasma membrane lipid phosphatidylserine (PS) asymmetry (175,341,342) that is followed by a later phase with DNA degradation (20,343-346). Usually DNA destruction is considered a committed step, but reversal of membrane PS exposure can prevent microglial and macrophage engulfment of cells tagged with PS externalization (72,204,347-349).

Coupled to the onset of the apoptotic cascade can be the induction of oxidative stress and the generation of reactive oxygen species (ROS) (20,258,350,351). ROS can lead to DNA destruction, senescence, organelle injury, protein misfolding, and neuronal synaptic dysfunction (41,43,52,95,149,351,352). For the most part, endogenous systems that include vitamins B, C, D, and K (54,353-356) and glutathione peroxidase (356,357) can prevent cellular injury during oxidative stress. Yet, pathology ensues when these systems are overwhelmed.

EPO can block apoptotic cell death under multiple conditions (Table 1). During ischemic reperfusion injury, EPO prevents tubular cell apoptosis through Wnt signaling pathways (318). In familial amyloidotic polyneuropathy, depressed levels of EPO may be associated with increased oxidative stress and apoptotic cell injury (358). EPO can prevent apoptotic injury against advanced glycation end-product (AGE) exposure in Schwann cells (359), sepsis (229,360), cerebral ischemia (313,345,361), A β toxicity (186,218,358,362-364), neuronal kainate-induced oxidative stress (26), vascular oxygen-glucose deprivation (194,221,310), hypoxia and anoxia (199,365,366), retinal disease (367,368), experimental models of diabetes mellitus (194,204,314, 316, 369, 370), and toxins that destroy microglial cells (146,166,186,227,368).

In relation to blocking the detrimental effects of oxidative stress and ROS, EPO protects endothelial cells (144,194,199,203,204,214,220,221,316,368,371-376), neurons (26,210,237,345,362,377-382), astrocytes (377,383-385), and microglia (166,186,196,227,368, 381). During oxidative stress, EPO also preserves neurogenesis (336,386), stem cell development (126,220, 237,312,372,387), and promotes erythroid progenitor cell development with the modulation of FoxO3a activity (29,169,237,307). EPO can prevent free radical cell injury (210,215,371,388-390) through the blockade of ROS generation (212,339,370,381,391).

5.2. Autophagy

In addition to apoptosis, autophagy is another pathway of programmed cell death that is controlled by EPO. Autophagy recycles components in the cell cytoplasm to remove non-functional organelles for disposal and tissue remodeling (14,342,392,393). Autophagy is classified as microautophagy, chaperone-mediated

autophagy, and macroautophagy (122). Macroautophagy is the principal category of autophagy and consists of the sequestration of cytoplasmic proteins and organelles into autophagosomes. Autophagosomes combine with lysosomes for degradation and recycling (122,393-396). Microautophagy leads to the invagination of lysosomal membranes for the sequestration and digestion of cytoplasmic components. Chaperone-mediated autophagy uses cytosolic chaperones for the transport of cytoplasmic components across lysosomal membranes (6).

EPO can block autophagy through the activation of mTOR (16,397,398) (Table 1). Activation of mTOR blocks autophagy by phosphorylating autophagic related genes (*Atg*) and proteins that include Atg13 and ULKs to inhibit the UNC like kinase complex ULK-Atg13-FIP200 (7). EPO, Akt, and mTOR activation protect against increased activity of autophagy in epithelial cells (213) and promote protection against hypoxia and oxidative stress in retinal progenitor cells (337). EPO controls excessive autophagy that precedes apoptosis during experimental neonatal necrotizing enterocolitis (213). EPO also can modify the activity of autophagy and limit neonatal brain damage in the developing rodent during hyperoxia exposure and oxygen toxicity (399). Under some experimental conditions in neuronal cell line models, EPO can suppress apoptotic cell injury through the increased activity of AMPK and limited autophagy activity (400).

6. ERYTHROPOIETIN AND CLINICAL EFFICACY

The remarkable progress in understanding the protective signaling pathways of EPO has provided fertile ground for the launch of several clinical studies evaluating the protective role of EPO in the nervous system. At present, more than 60 ongoing or completed clinical trials are listed on the National Institutes of Health website ClinicalTrials.gov for EPO and disorders of the nervous system. In recent trials, new information has been gained to translate the findings of basic research for EPO in the nervous system into potential clinical utility.

EPO may provide neuroprotection against developmental impairment in preterm infants (Table 1). EPO has been reported to offer developmental cognitive support in humans with the observation that elevated EPO concentrations during infant maturation have been correlated with increased Mental Development Index scores (401). In a randomized, double-blind placebo-controlled study involving preterm infants, recombinant EPO (3000 IU) was administered before 3 hours of age, at 12-18 hours of age, and 36-42 hours of age. EPO was demonstrated to improve white matter development assessed by diffusion tensor imaging and tract-based spatial statistics (400). Other work has supported that

EPO (3000 IU) administered within 42 hours of age in preterm infants reduced the risk of brain injury assessed by magnetic resonance imaging (402).

However, the neuroprotective ability of EPO may have greater utility in the immature brain than compared to the adult brain with severe dysfunction. In a randomized trial of 200 patients with closed head injury and the inability to follow commands, EPO (500 IU/kg) was administered for 3 days then weekly for 2 weeks in the setting of maintaining hemoglobin concentration of greater than 10 g/dL. Following the completion of the study, EPO or maintaining hemoglobin concentration of greater than 10 g/dL did not result in improved neurological outcome at 6 months (403). Studies with patients suffering from ischemic stroke and receiving human chorionic gonadotropin alfa followed by EPO also did not show improvement in neurological recovery (404).

Yet, in a study with long-term administration of the biosimilar epoetin α (Binocrit) in elderly patients with myelodysplastic syndromes, cognitive function appeared to improve that may be related to resolution of anemia (405). In a limited study with 26 PD patients, recombinant EPO administration improved cardiovascular autonomic dysfunction and cognition, but did not affect motor function of the patients (406). In relation to the cardiovascular benefits potentially gained from EPO, several studies suggest that at least high concentrations of EPO may not be warranted to protect cardiac function (142,168,407-409). Yet, some work indicates that low concentrations of EPO may be beneficial to the cardiovascular system (212,360,410) which could subsequently benefit neurological function.

7. FUTURE CONSIDERATIONS FOR ERYTHROPOIETIN

With the increased life expectancy of the global population, the incidence of acute and chronic neurodegenerative disorders is expected to increase. Presently, more than 30 million individuals suffer from disorders of the nervous system throughout the world (4,5). EPO and its signaling pathways offer exciting prospects for the treatment of neurodegenerative disorders. EPO governs a number of critical pathways that support cells of the nervous system to include Akt, sirutins, Wnt signaling, and mTOR. In addition, EPO has been shown to impact programmed cell death pathways that involve apoptosis and autophagy and target specific "pro-apoptotic" proteins such as forkhead transcription factors. Translational of the critical cellular pathways involving EPO into effective clinical treatments for the nervous system has been promising for fetal brain injury. Additional work is necessary to determine the role of EPO for treatment of the adult brain that involves trauma, cognition, ischemic brain disease, related cardiovascular disease, and degenerative disorders of

the nervous system. Outcomes from these studies can be heavily influenced by multiple factors that include EPO concentration, timing of administration, onset and severity of the underlying disorder, and the targeting of specific down-stream pathways for EPO.

Yet, use of EPO as a clinical neuroprotective entity brings with it a number of considerations. EPO is a growth factor and controls cellular proliferative pathways that can lead to tumorigenesis. EPO (411-413) and pathways that involve Akt (414-416), mTOR (417-419), and Wnt signaling (268,271, 279, 288, 420) can promote unchecked tumor growth. EPO also may be involved with the self-renewal of tumor-initiating cells (421).

EPO may have detrimental vascular effects and be contraindicated under specific circumstances, such as in patients with poorly controlled hypertension, individuals with known blood viscosity concerns, and in those with diabetic complications of the nervous system. EPO can limit FoxO activity in addition to other pathways to reduce ischemic stroke size (313). Yet, EPO may increase the risk of vascular complications in the brain. EPO administration results in a two-fold increase in stroke that is not attributed to any baseline characteristic or to blood pressure, hemoglobin, platelet count, or treatment dose of EPO in patients with diabetes mellitus and renal disease (422). Blood viscosity has been reported to be increased with a reduction in cerebral blood flow in mice that overexpress EPO (423). EPO also can increase vascular responsiveness (424) and may lead to hypertension (29,142,425). For the retina, elevated EPO concentrations may be associated with proliferative diabetic retinopathy (426) that is tied to excessive microvascular angiogenesis. Sustained erythrocytosis with EPO also may activate inflammatory pathways and result in blood-brain barrier dysfunction (427).

Focusing upon the cellular signaling pathways of EPO could potentially enhance clinical efficacy for the treatment of neurodegenerative disorders and limit unwanted side effects for EPO. For example, targeting pathways of EPO, such as mTOR, that can finely control the activity of apoptosis and autophagy may foster significant benefit for the treatment of cognitive neurodegenerative disorders. In microglial cells of the nervous system, A β can inhibit mTOR signaling through PRAS40 (186,428) that leads to apoptosis and may foster disease progression during Ab toxicity. EPO, through the activation of mTOR can limit PRAS40 activity and block apoptotic cell injury (310). Increased mTOR signaling also may be necessary to regulate the β -site amyloid precursor protein (APP)-cleaving enzyme 1 (β -secretase, BACE1) that promotes Ab accumulation in AD, since elevated mTORC1 activity reduces BACE1 and is able to limit A β generation (429). In animal models of AD, loss of mTOR signaling has been shown

to impair long-term potentiation and synaptic plasticity that can be reversed with the up-regulation of mTOR signaling (430). Conversely, other work suggests that some degree of inhibition of mTOR may be necessary to enhance A β clearance and improve spatial learning through the activation of autophagy (431). Future work that recognizes the fine interplay of the signaling pathways of EPO could yield the greatest benefits for the successful treatment of multiple disorders in the nervous system.

8. ACKNOWLEDGMENTS

This research was supported by the following grants to Kenneth Maiese: American Diabetes Association, American Heart Association, NIH NIEHS, NIH NIA, NIH NINDS, and NIH ARRA.

9. REFERENCES

1. A. Hayutin: Global demographic shifts create challenges and opportunities. *PREA Quarterly*, (Fall), 46-53 (2007)
2. A. M. Minino: Death in the United States, 2011. *NCHS Data Brief*(115), 1-8 (2013)
3. World Health Organization: Description of the global burden of NCDs, their risk factors and determinants. *Global status report on noncommunicable diseases 2010*(April), 1-176 (2011)
4. K. Maiese: SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer. *World J Stem Cells*, 7(2), 235-42 (2015)
DOI: 10.4252/wjsc.v7.i2.235
5. A. Martin, C. A. Tegla, C. D. Cudrici, A. M. Kruszewski, P. Azimzadeh, D. Boodhoo, A. P. Mekala, V. Rus and H. Rus: Role of SIRT1 in autoimmune demyelination and neurodegeneration. *Immunol Res*, 61(3), 187-97 (2015)
DOI: 10.1007/s12026-014-8557-5
6. K. Maiese: Driving neural regeneration through the mammalian target of rapamycin. *Neural Regen Res*, 9(15), 1413-7 (2014)
DOI: 10.4103/1673-5374.139453
7. K. Maiese: Taking aim at Alzheimer's disease through the mammalian target of rapamycin. *Ann Med*, 46(8), 587-596 (2014)
DOI: 10.3109/07853890.2014.941921
8. K. Maiese, Z. Z. Chong, J. Hou and Y. C. Shang: New strategies for Alzheimer's disease and cognitive impairment. *Oxid Med Cell Longev*, 2(5), 279-89 (2009)
DOI: 10.4161/oxim.2.5.9990
9. A. Agis-Torres, M. Solhuber, M. Fernandez and J. M. Sanchez-Montero: Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease. *Curr Neuropharmacol*, 12(1), 2-36 (2014)
DOI: 10.2174/1570159X113116660047
10. C. M. Filley, Y. D. Rollins, C. A. Anderson, D. B. Arciniegas, K. L. Howard, J. R. Murrell, P. J. Boyer, B. K. Kleinschmidt-DeMasters and B. Ghetti: The genetics of very early onset alzheimer disease. *Cogn Behav Neurol*, 20(3), 149-56 (2007)
DOI: 10.1097/WNN.0b013e318145a8c8
11. Z. Z. Chong, Y. C. Shang, S. Wang and K. Maiese: Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. *Prog Neurobiol*, 99(2), 128-148 (2012)
DOI: 10.1016/j.pneurobio.2012.08.001
12. A. K. Mishra, M. S. Ur Rasheed, S. Shukla, M. K. Tripathi, A. Dixit and M. P. Singh: Aberrant Autophagy and Parkinsonism: Does Correction Rescue from Disease Progression? *Mol Neurobiol* (2014)
13. K. Maiese: Cutting through the Complexities of mTOR for the Treatment of Stroke. *Curr Neurovasc Res*, 11(2), 177-186 (2014)
DOI: 10.2174/1567202611666140408104831
14. V. P. Nakka, P. Prakash-Babu and R. Vemuganti: Crosstalk Between Endoplasmic Reticulum Stress, Oxidative Stress, and Autophagy: Potential Therapeutic Targets for Acute CNS Injuries. *Mol Neurobiol* (2014)
DOI: 10.1007/s12035-014-9029-6
15. W. Chen, Y. Sun, K. Liu and X. Sun: Autophagy: a double-edged sword for neuronal survival after cerebral ischemia. *Neural Regen Res*, 9(12), 1210-6 (2014)
DOI: 10.4103/1673-5374.135329
16. K. Maiese: mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. *World J Diabetes*, 6(2), 217-24 (2015)
DOI: 10.4239/wjd.v6.i2.217
17. A. M. Minino and S. L. Murphy: Death in the United States, 2010. *NCHS Data Brief*(99), 1-8 (2012)

18. N. Esser, N. Paquot and A. J. Scheen: Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. *Expert Opin Investig Drugs*, 24(3), 283-307 (2015)
DOI: 10.1517/13543784.2015.974804
19. K. Maiese: New Insights for Oxidative Stress and Diabetes Mellitus. *Oxid Med Cell Longev*, 2015(Article ID 875961) (2015)
DOI: 10.1155/2015/875961
20. Z. Z. Chong, F. Li and K. Maiese: Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. *Prog Neurobiol*, 75(3), 207-46 (2005)
DOI: 10.1016/j.pneurobio.2005.02.004
21. G. Harish, A. Mahadevan, N. Pruthi, S. K. Sreenivasamurthy, V. N. Puttamalles, T. S. Keshava Prasad, S. K. Shankar and M. S. M: Characterization of traumatic brain injury in human brains reveals distinct cellular and molecular changes in contusion and pericontusion. *J Neurochem* (2015)
22. J. Lee, X. Gu, L. Wei, Z. Wei, T. A. Dix and S. P. Yu: Therapeutic Effects of Pharmacologically induced Hypothermia against Traumatic Brain Injury in Mice. *J Neurotrauma* (2014)
DOI: 10.1089/neu.2013.3251
23. K. Maiese: Coma and impaired consciousness. The Merck Manual, 19th Professional Edition (2011)
24. J. W. Wang, H. D. Wang, Z. X. Cong, X. M. Zhou, J. G. Xu, Y. Jia and Y. Ding: Puerarin ameliorates oxidative stress in a rodent model of traumatic brain injury. *J Surg Res*, 186(1), 328-37 (2014)
DOI: 10.1016/j.jss.2013.08.027
25. P. R. Kumar, M. M. Essa, S. Al-Adawi, G. Dradekh, M. A. Memon, M. Akbar and T. Manivasagam: Omega-3 Fatty acids could alleviate the risks of traumatic brain injury - a mini review. *J Tradit Complement Med*, 4(2), 89-92 (2014)
DOI: 10.4103/2225-4110.130374
26. D. C. Costa, N. Alva, L. Trigueros, A. Gamez, T. Carbonell and R. Rama: Intermittent hypobaric hypoxia induces neuroprotection in kainate-induced oxidative stress in rats. *J Mol Neurosci*, 50(3), 402-10 (2013)
DOI: 10.1007/s12031-012-9945-8
27. L. Dong, S. Zhou, X. Yang, Q. Chen, Y. He and W. Huang: Magnolol protects against oxidative stress-mediated neural cell damage by modulating mitochondrial dysfunction and PI3K/Akt signaling. *J Mol Neurosci*, 50(3), 469-81 (2013)
DOI: 10.1007/s12031-013-9964-0
28. M. B. Gomes and C. A. Negrato: Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. *Diabetol Metab Syndr*, 6(1), 80 (2014)
DOI: 10.1186/1758-5996-6-80
29. K. Maiese, Z. Z. Chong, J. Hou and Y. C. Shang: Oxidative stress: Biomarkers and novel therapeutic pathways. *Exp Gerontol*, 45(3), 217-34 (2010)
DOI: 10.1016/j.exger.2010.01.004
30. J. Mehla, M. Pahuja, P. Gupta, S. Dethle, A. Agarwal and Y. K. Gupta: Clitoria ternatea ameliorated the intracerebroventricularly injected streptozotocin induced cognitive impairment in rats: behavioral and biochemical evidence. *Psychopharmacology (Berl)*, 230(4), 589-605 (2013)
DOI: 10.1007/s00213-013-3185-7
31. M. B. Nejm, A. A. Haidar, M. J. Marques, A. E. Hirata, F. N. Nogueira, E. A. Cavalheiro, F. A. Scorza and R. M. Cysneiros: Fish oil provides protection against the oxidative stress in pilocarpine model of epilepsy. *Metab Brain Dis* (2015)
DOI: 10.1007/s11011-015-9666-0
32. D. Radak, I. Resanovic and E. R. Isenovic: Link Between Oxidative Stress and Acute Brain Ischemia. *Angiology* (2013)
33. A. Uzdensky, E. Berezhnaya, A. Khaitin, V. Kovaleva, M. Komandirov, M. Neginskaya, M. Rudkovskii and S. Sharifulina: Protection of the Crayfish Mechanoreceptor Neuron and Glial Cells from Photooxidative Injury by Modulators of Diverse Signal Transduction Pathways. *Mol Neurobiol* (2015)
DOI: 10.1007/s12035-015-9237-8
34. Y. J. Xin, B. Yuan, B. Yu, Y. Q. Wang, J. J. Wu, W. H. Zhou and Z. Qiu: Tet1-mediated DNA demethylation regulates neuronal cell death induced by oxidative stress. *Sci Rep*, 5, 7645 (2015)
DOI: 10.1038/srep07645
35. M. Bajda, N. Guzior, M. Ignasik and B.

- Malawska: Multi-target-directed ligands in Alzheimer's disease treatment. *Curr Med Chem*, 18(32), 4949-75 (2011)
DOI: 10.2174/092986711797535245
36. Y. Y. Cao, L. Wang, H. Ge, X. L. Lu, Z. Pei, Q. Gu and J. Xu: Salvianolic acid A, a polyphenolic derivative from *Salvia miltiorrhiza* bunge, as a multifunctional agent for the treatment of Alzheimer's disease. *Mol Divers*, 17(3), 515-24 (2013)
DOI: 10.1007/s11030-013-9452-z
 37. V. Exil, L. Ping, Y. Yu, S. Chakraborty, S. W. Caito, K. S. Wells, P. Karki, E. Lee and M. Aschner: Activation of MAPK and FoxO by manganese (Mn) in rat neonatal primary astrocyte cultures. *PLoS One*, 9(5), e94753 (2014)
DOI: 10.1371/journal.pone.0094753
 38. P. Grammas, D. Tripathy, A. Sanchez, X. Yin and J. Luo: Brain microvasculature and hypoxia-related proteins in Alzheimer's disease. *Int J Clin Exp Pathol*, 4(6), 616-27 (2011)
 39. S. L. Sensi, P. Paoletti, J. Y. Koh, E. Aizenman, A. I. Bush and M. Hershfinkel: The Neurophysiology and Pathology of Brain Zinc. *J Neurosci*, 31(45), 16076-16085 (2011)
DOI: 10.1523/JNEUROSCI.3454-11.2011
 40. M. M. Aranha, D. M. Santos, S. Sola, C. J. Steer and C. M. Rodrigues: miR-34a regulates mouse neural stem cell differentiation. *PLoS One*, 6(8), e21396 (2011)
DOI: 10.1371/journal.pone.0021396
 41. Z. Z. Chong, Y. C. Shang, S. Wang and K. Maiese: SIRT1: New avenues of discovery for disorders of oxidative stress. *Expert Opin Ther Targets*, 16(2), 167-78 (2012)
DOI: 10.1517/14728222.2012.648926
 42. W. Duan: Targeting sirtuin-1 in Huntington's disease: rationale and current status. *CNS Drugs*, 27(5), 345-52 (2013)
DOI: 10.1007/s40263-013-0055-0
 43. J. Li, L. Feng, Y. Xing, Y. Wang, L. Du, C. Xu, J. Cao, Q. Wang, S. Fan, Q. Liu and F. Fan: Radioprotective and antioxidant effect of resveratrol in hippocampus by activating sirt1. *Int J Mol Sci*, 15(4), 5928-39 (2014)
DOI: 10.3390/ijms15045928
 44. D. J. Liu, D. Hammer, D. Komlos, K. Y. Chen, B. L. Firestein and A. Y. Liu: SIRT1 knockdown promotes neural differentiation and attenuates the heat shock response. *J Cell Physiol*, 229(9), 1224-35 (2014)
DOI: 10.1002/jcp.24556
 45. S. Saharan, D. J. Jhaveri and P. F. Bartlett: SIRT1 regulates the neurogenic potential of neural precursors in the adult subventricular zone and hippocampus. *J Neurosci Res*, 91(5), 642-59 (2013)
DOI: 10.1002/jnr.23199
 46. Q. Sun, N. Jia, W. Wang, H. Jin, J. Xu and H. Hu: Activation of SIRT1 by curcumin blocks the neurotoxicity of amyloid-beta25-35 in rat cortical neurons. *Biochem Biophys Res Commun*, 448(1), 89-94 (2014)
DOI: 10.1016/j.bbrc.2014.04.066
 47. S. Wang, Z. Z. Chong, Y. C. Shang and K. Maiese: WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. *Curr Neurovasc Res*, 10(1), 54-60 (2013)
DOI: 10.2174/156720213804805945
 48. H. Xiong, M. Dai, Y. Ou, J. Pang, H. Yang, Q. Huang, S. Chen, Z. Zhang, Y. Xu, Y. Cai, M. Liang, X. Zhang, L. Lai and Y. Zheng: SIRT1 expression in the cochlea and auditory cortex of a mouse model of age-related hearing loss. *Exp Gerontol*, 51, 8-14 (2014)
DOI: 10.1016/j.exger.2013.12.006
 49. C. Canto, A. A. Sauve and P. Bai: Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. *Mol Aspects Med*, 34(6), 1168-201 (2013)
DOI: 10.1016/j.mam.2013.01.004
 50. Z. Z. Chong, S. H. Lin, F. Li and K. Maiese: The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through Akt, Bad, PARP, and mitochondrial associated "anti-apoptotic" pathways. *Curr Neurovasc Res*, 2(4), 271-85 (2005)
DOI: 10.2174/156720205774322584
 51. I. K. Kim, K. J. Lee, S. Rhee, S. B. Seo and J. H. Pak: Protective effects of peroxiredoxin 6 overexpression on amyloid beta-induced apoptosis in PC12 cells. *Free Radic Res*, 47(10), 836-46 (2013)
DOI: 10.3109/10715762.2013.833330
 52. S. H. Kwon, S. I. Hong, S. X. Ma, S. Y. Lee and C. G. Jang: 3',4',7-trihydroxyflavone prevents apoptotic cell death in neuronal cells from

- hydrogen peroxide-induced oxidative stress. *Food Chem Toxicol* (2015)
DOI: 10.1016/j.fct.2015.02.014
53. K. Maiese and Z. Z. Chong: Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. *Trends Pharmacol Sci*, 24(5), 228-32 (2003)
DOI: 10.1016/S0165-6147(03)00078-6
 54. K. Maiese, Z. Z. Chong, J. Hou and Y. C. Shang: The vitamin nicotinamide: translating nutrition into clinical care. *Molecules*, 14(9), 3446-85 (2009)
DOI: 10.3390/molecules14093446
 55. L. L. Pan, X. H. Liu, Y. L. Jia, D. Wu, Q. H. Xiong, Q. H. Gong, Y. Wang and Y. Z. Zhu: A novel compound derived from danshensu inhibits apoptosis via upregulation of heme oxygenase-1 expression in SH-SY5Y cells. *Biochim Biophys Acta*, 1830(4), 2861-71 (2013)
DOI: 10.1016/j.bbagen.2013.01.008
 56. R. Pan, C. Chen, W. L. Liu and K. J. Liu: Zinc promotes the death of hypoxic astrocytes by upregulating hypoxia-induced hypoxia-inducible factor-1 α expression via poly(ADP-ribose) polymerase-1. *CNS Neurosci Ther*, 19(7), 511-20 (2013)
DOI: 10.1111/cns.12098
 57. C. S. Siegel and L. D. McCullough: NAD⁺ and nicotinamide: sex differences in cerebral ischemia. *Neuroscience*, 237, 223-31 (2013)
DOI: 10.1016/j.neuroscience.2013.01.068
 58. E. Turunc Bayrakdar, G. Armagan, Y. Uyanikgil, L. Kanit, E. Koylu and A. Yalcin: Ex vivo protective effects of nicotinamide and 3-aminobenzamide on rat synaptosomes treated with A β (1-42). *Cell Biochem Funct* (2014)
DOI: 10.1002/cbf.3049
 59. E. Turunc Bayrakdar, Y. Uyanikgil, L. Kanit, E. Koylu and A. Yalcin: Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in A β (1-42)-induced rat model of Alzheimer's disease. *Free Radic Res*, 48(2), 146-58 (2014)
DOI: 10.3109/10715762.2013.857018
 60. T. Chen, L. Zhang, Y. Qu, K. Huo, X. Jiang and Z. Fei: The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. *Int J Mol Med*, 29(4), 630-6 (2012)
 61. Z. Z. Chong, J. Kang, F. Li and K. Maiese: mGluR1 Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways. *Curr Neurovasc Res*, 2(3), 197-211 (2005)
DOI: 10.2174/1567202054368317
 62. Z. Z. Chong, F. Li and K. Maiese: Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. *Curr Neurovasc Res*, 3(2), 107-17 (2006)
DOI: 10.2174/156720206776875830
 63. S. Dolan, M. D. Gunn, C. Crossan and A. M. Nolan: Activation of metabotropic glutamate receptor 7 in spinal cord inhibits pain and hyperalgesia in a novel formalin model in sheep. *Behav Pharmacol*, 22(5-6), 582-8 (2011)
DOI: 10.1097/FBP.0b013e3283478802
 64. H. Domin, K. Golembiowska, D. Jantas, K. Kaminska, B. Zieba and M. Smialowska: Group III mGlu Receptor Agonist, ACPT-I, Exerts Potential Neuroprotective Effects *In vitro* and *In vivo*. *Neurotox Res* (2014)
DOI: 10.1007/s12640-013-9455-7
 65. H. Domin, D. Jantas and M. Smialowska: Neuroprotective effects of the allosteric agonist of metabotropic glutamate receptor 7 AMN082 on oxygen-glucose deprivation- and kainate-induced neuronal cell death. *Neurochem Int* (2015)
DOI: 10.1016/j.neuint.2014.12.010
 66. D. Jantas, A. Greda, S. Golda, M. Korostynski, B. Grygier, A. Roman, A. Pilc and W. Lason: Neuroprotective effects of metabotropic glutamate receptor group II and III activators against MPP(+)-induced cell death in human neuroblastoma SH-SY5Y cells: the impact of cell differentiation state. *Neuropharmacology*, 83, 36-53 (2014)
DOI: 10.1016/j.neuropharm.2014.03.019
 67. S. H. Lin and K. Maiese: The metabotropic glutamate receptor system protects against ischemic free radical programmed cell death in rat brain endothelial cells. *J Cereb Blood Flow Metab*, 21(3), 262-75. (2001)
DOI: 10.1097/00004647-200103000-00010
 68. K. Maiese, Z. Z. Chong, Y. C. Shang and J. Hou: Therapeutic promise and principles:

- Metabotropic glutamate receptors. *Oxid Med Cell Longev*, 1(1), 1-14 (2008)
DOI: 10.4161/oxim.1.1.6842
69. K. Maiese, A. Vincent, S. H. Lin and T. Shaw: Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. *J Neurosci Res*, 62(2), 257-272 (2000)
DOI: 10.1002/1097-4547(20001015)62:2<257:AID-JNR10>3.0.CO;2-H
 70. S. Nasrniya and M. R. Bigdeli: Ischemic tolerance induced by normobaric hyperoxia and evaluation of group I and II metabotropic glutamate receptors. *Curr Neurovasc Res*, 10(1), 21-8 (2013)
DOI: 10.2174/156720213804805981
 71. W. Y. Wang, H. Wang, Y. Luo, L. J. Jia, J. N. Zhao, H. H. Zhang, Z. W. Ma, Q. S. Xue and B. W. Yu: The effects of metabotropic glutamate receptor 7 allosteric agonist N,N'-dibenzhydriethane-1,2-diamine dihydrochloride on developmental sevoflurane neurotoxicity: role of extracellular signal-regulated kinase 1 and 2 mitogen-activated protein kinase signaling pathway. *Neuroscience*, 205, 167-77 (2012)
DOI: 10.1016/j.neuroscience.2011.12.039
 72. C. J. Williams and D. T. Dexter: Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease. *J Neurochem*, 129(1), 4-20 (2014)
DOI: 10.1111/jnc.12608
 73. I. Aksu, M. Ates, B. Baykara, M. Kiray, A. R. Sisman, E. Buyuk, B. Baykara, C. Cetinkaya, H. Gumus and N. Uysal: Anxiety correlates to decreased blood and prefrontal cortex IGF-1 levels in streptozotocin induced diabetes. *Neurosci Lett*, 531(2), 176-81 (2012)
DOI: 10.1016/j.neulet.2012.10.045
 74. S. Cardoso, R. X. Santos, S. C. Correia, C. Carvalho, M. S. Santos, I. Baldeiras, C. R. Oliveira and P. I. Moreira: Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. *Neurobiol Dis*, 49C, 1-12 (2012)
 75. D. Kapogiannis, A. Boxer, J. B. Schwartz, E. L. Abner, A. Biragyn, U. Masharani, L. Frassetto, R. C. Petersen, B. L. Miller and E. J. Goetzl: Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. *FASEB J* (2014)
 76. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Novel directions for diabetes mellitus drug discovery. *Expert Opin Drug Discov*, 8(1), 35-48 (2013)
DOI: 10.1517/17460441.2013.736485
 77. X. Y. Mao, D. F. Cao, X. Li, J. Y. Yin, Z. B. Wang, Y. Zhang, C. X. Mao, H. H. Zhou and Z. Q. Liu: Huperzine A ameliorates cognitive deficits in streptozotocin-induced diabetic rats. *Int J Mol Sci*, 15(5), 7667-83 (2014)
DOI: 10.3390/ijms15057667
 78. Z. Zhao, G. Huang, B. Wang and Y. Zhong: Inhibition of NF-kappaB activation by Pyrrolidine dithiocarbamate partially attenuates hippocampal MMP-9 activation and improves cognitive deficits in streptozotocin-induced diabetic rats. *Behav Brain Res*, 238, 44-7 (2013)
DOI: 10.1016/j.bbr.2012.10.018
 79. A. Alttoa, K. Koiv, T. A. Hinsley, A. Brass and J. Harro: Differential gene expression in a rat model of depression based on persistent differences in exploratory activity. *Eur Neuropsychopharmacol*, 20(5), 288-300 (2010)
DOI: 10.1016/j.euroneuro.2009.09.005
 80. A. O. Estevez, K. L. Morgan, N. J. Szewczyk, D. Gems and M. Estevez: The neurodegenerative effects of selenium are inhibited by FOXO and PINK1/PTEN regulation of insulin/insulin-like growth factor signaling in *Caenorhabditis elegans*. *Neurotoxicology*, 41, 28-43 (2014)
DOI: 10.1016/j.neuro.2013.12.012
 81. R. Lakhani, K. R. Vogel, A. Till, J. Liu, S. F. Burnett, K. M. Gibson and S. Subramani: Defects in GABA metabolism affect selective autophagy pathways and are alleviated by mTOR inhibition. *EMBO Mol Med* (2014)
DOI: 10.1002/emmm.201303356
 82. S. Semaan, J. Wu, Y. Gan, Y. Jin, G. H. Li, J. F. Kerrigan, Y. C. Chang and Y. Huang: Hyperactivation of BDNF-TrkB Signaling Cascades in Human Hypothalamic Hamartoma (HH): A Potential Mechanism Contributing to Epileptogenesis. *CNS Neurosci Ther* (2014)
 83. K. Y. Yoo, S. H. Kwon, C. H. Lee, B. Yan, J. H. Park, J. H. Ahn, J. H. Choi, T. G. Ohk, J. H. Cho and M. H. Won: FoxO3a changes in

- pyramidal neurons and expresses in non-pyramidal neurons and astrocytes in the gerbil hippocampal CA1 region after transient cerebral ischemia. *Neurochem Res*, 37(3), 588-95 (2012)
DOI: 10.1007/s11064-011-0648-2
84. P. K. Bahia, V. Pugh, K. Hoyland, V. Hensley, M. Rattray and R. J. Williams: Neuroprotective effects of phenolic antioxidant tBHQ associate with inhibition of FoxO3a nuclear translocation and activity. *J Neurochem*, 123(1), 182-91 (2012)
DOI: 10.1111/j.1471-4159.2012.07877.x
 85. J. Chen, H. Mao, H. Zou, W. Jin, L. Ni, K. Ke, M. Cao and W. Shi: Up-regulation of ski-interacting protein in rat brain cortex after traumatic brain injury. *J Mol Histol*, 44(1), 1-10 (2013)
DOI: 10.1007/s10735-012-9444-9
 86. Z. Z. Chong, S. H. Lin and K. Maiese: The NAD⁺ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. *J Cereb Blood Flow Metab*, 24(7), 728-43 (2004)
DOI: 10.1097/01.WCB.0000122746.72175.0E
 87. M. De Butte-Smith, R. S. Zukin and A. M. Etgen: Effects of global ischemia and estradiol pretreatment on phosphorylation of Akt, CREB and STAT3 in hippocampal CA1 of young and middle-aged female rats. *Brain Res*, 1471, 118-28 (2012)
DOI: 10.1016/j.brainres.2012.06.036
 88. A. Domanskyi, H. Alter, M. A. Vogt, P. Gass and I. A. Vinnikov: Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance. *Front Cell Neurosci*, 8, 275 (2014)
DOI: 10.3389/fncel.2014.00275
 89. E. C. Genin, N. Caron, R. Vandenbosch, L. Nguyen and B. Malgrange: Concise review: forkhead pathway in the control of adult neurogenesis. *Stem Cells*, 32(6), 1398-407 (2014)
DOI: 10.1002/stem.1673
 90. F. Gilels, S. T. Paquette, J. Zhang, I. Rahman and P. M. White: Mutation of Foxo3 causes adult onset auditory neuropathy and alters cochlear synapse architecture in mice. *J Neurosci*, 33(47), 18409-24 (2013)
DOI: 10.1523/JNEUROSCI.2529-13.2013
 91. F. Li, Z. Z. Chong and K. Maiese: Navigating novel mechanisms of cellular plasticity with the NAD⁺ precursor and nutrient nicotinamide. *Front Biosci*, 9, 2500-2520 (2004)
DOI: 10.2741/1412
 92. W. Liu, X. Liu, H. Yang, X. Zhu, H. Yi, X. Zhu and J. Zhang: Phosphorylated retinoblastoma protein (p-Rb) is involved in neuronal apoptosis after traumatic brain injury in adult rats. *J Mol Histol*, 44(2), 147-58 (2013)
DOI: 10.1007/s10735-013-9481-z
 93. K. Maiese: FoxO proteins in the nervous system. *Anal Cell Pathol (Amst)*, 2015(Article ID 569392) (2015)
DOI: 10.1155/2015/569392
 94. K. Maiese, Z. Z. Chong and Y. C. Shang: OutFOXing disease and disability: the therapeutic potential of targeting FoxO proteins. *Trends Mol Med*, 14(5), 219-27 (2008)
DOI: 10.1016/j.molmed.2008.03.002
 95. S. Peng, S. Zhao, F. Yan, J. Cheng, L. Huang, H. Chen, Q. Liu, X. Ji and Z. Yuan: HDAC2 selectively regulates FOXO3a-mediated gene transcription during oxidative stress-induced neuronal cell death. *J Neurosci*, 35(3), 1250-9 (2015)
DOI: 10.1523/JNEUROSCI.2444-14.2015
 96. M. Sertbas, K. Ulgen and T. Cakir: Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network. *FEBS Open Bio*, 4, 542-53 (2014)
DOI: 10.1016/j.fob.2014.05.006
 97. T. Tanaka and M. Iino: Knockdown of Sec8 promotes cell-cycle arrest at G/S phase by inducing p21 via control of FOXO proteins. *FEBS J* (2013)
 98. Q. Xie, Y. Hao, L. Tao, S. Peng, C. Rao, H. Chen, H. You, M. Q. Dong and Z. Yuan: Lysine methylation of FOXO3 regulates oxidative stress-induced neuronal cell death. *EMBO Rep*, 13(4), 371-377 (2012)
DOI: 10.1038/embor.2012.25
 99. E. Zeldich, C. D. Chen, T. A. Colvin, E. A. Bove-Fenderson, J. Liang, T. B. Tucker Zhou, D. A. Harris and C. R. Abraham: The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. *J Biol Chem*, 289(35), 24700-15 (2014)
DOI: 10.1074/jbc.M114.567321

100. M. Albiero, N. Poncina, M. Tjwa, S. Ciciliot, L. Menegazzo, G. Ceolotto, S. Vigili de Kreutzenberg, R. Moura, M. Giorgio, P. Pelicci, A. Avogaro and G. P. Fadini: Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. *Diabetes*, 63(4), 1353-65 (2014)
DOI: 10.2337/db13-0894
101. D. Angelis, T. D. Fontanez-Nieves and M. Delivoria-Papadopoulos: The Role of Src Kinase in the Caspase-1 Pathway After Hypoxia in the Brain of Newborn Piglets. *Neurochem Res* (2014)
102. Z. Z. Chong, S. H. Lin, J. Q. Kang and K. Maiese: The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. *Cell Mol Neurobiol*, 23(4-5), 561-78 (2003)
DOI: 10.1023/A:1025158314016
103. Z. Z. Chong and K. Maiese: The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. *Histol Histopathol*, 22(11), 1251-67 (2007)
104. Y. S. Huang, C. Y. Cheng, S. H. Chueh, D. Y. Hueng, Y. F. Huang, C. M. Chu, S. T. Wu, M. C. Tai, C. M. Liang, M. H. Liao, C. C. Chen, L. H. Shen and K. H. Ma: Involvement of SHP2 in focal adhesion, migration and differentiation of neural stem cells. *Brain Dev*, 34(8), 674-84 (2012)
DOI: 10.1016/j.braindev.2011.10.011
105. A. Jalsrai, T. Numakawa, Y. Ooshima, N. Adachi and H. Kunugi: Phosphatase-mediated intracellular signaling contributes to neuroprotection by flavonoids of *Iris tenuifolia*. *Am J Chin Med*, 42(1), 119-30 (2014)
DOI: 10.1142/S0192415X14500086
106. A. Jo, H. Park, S. H. Lee, S. H. Ahn, H. J. Kim, E. M. Park and Y. H. Choi: SHP-2 Binds to Caveolin-1 and Regulates Src Activity via Competitive Inhibition of CSK in Response to H₂O₂ in Astrocytes. *PLoS One*, 9(3), e91582 (2014)
DOI: 10.1371/journal.pone.0091582
107. J. H. Yun, S. J. Park, A. Jo, J. L. Kang, I. Jou, J. S. Park and Y. H. Choi: Caveolin-1 is involved in reactive oxygen species-induced SHP-2 activation in astrocytes. *Exp Mol Med*, 43(12), 660-8 (2011)
DOI: 10.3858/emmm.2011.43.12.075
108. J. A. Burket, A. D. Benson, A. H. Tang and S. I. Deutsch: Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders. *Brain Res Bull*, 100, 70-5 (2014)
DOI: 10.1016/j.brainresbull.2013.11.005
109. A. Chen, L. J. Xiong, Y. Tong and M. Mao: Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway. *Mol Med Rep*, 8(4), 1011-6 (2013)
DOI: 10.3892/mmr.2013.1628
110. A. Francois, A. Rioux-Bilan, N. Quillard, B. Fernandez, T. Janet, D. Chassaing, M. Paccalin, F. Terro and G. Page: Longitudinal follow-up of autophagy and inflammation in brain of APPswePS1dE9 transgenic mice. *J Neuroinflammation*, 11(1), 139 (2014)
DOI: 10.1186/s12974-014-0139-x
111. C. Gubern, S. Camos, O. Hurtado, R. Rodriguez, V. G. Romera, M. Sobrado, R. Canadas, M. A. Moro, I. Lizasoain, J. Serena, J. Mallolas and M. Castellanos: Characterization of Gcf2/Lrrfp1 in experimental cerebral ischemia and its role as a modulator of Akt, mTOR and beta-catenin signaling pathways. *Neuroscience*, 268C, 48-65 (2014)
DOI: 10.1016/j.neuroscience.2014.02.051
112. M. Hadamitzky, A. Herring, K. Keyvani, R. Doenlen, U. Krugel, K. Bosche, K. Orlowski, H. Engler and M. Schedlowski: Acute systemic rapamycin induces neurobehavioral alterations in rats. *Behav Brain Res*, 273, 16-22 (2014)
DOI: 10.1016/j.bbr.2014.06.056
113. A. Jenwitheesuk, C. Nopparat, S. Mukda, P. Wongchitrat and P. Govitrapong: Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. *Int J Mol Sci*, 15(9), 16848-84 (2014)
DOI: 10.3390/ijms150916848
114. M. Ka, G. Condorelli, J. R. Woodgett and W. Y. Kim: mTOR regulates brain morphogenesis by mediating GSK3 signaling. *Development*, 141(21), 4076-86 (2014)
DOI: 10.1242/dev.108282
115. M. N. Kamarudin, N. A. Mohd Raflee, S. S. Syed Hussein, J. Y. Lo, H. Supriady and H. Abdul

- Kadir: (R)-(+)-alpha-Lipoic acid protected NG108-15 cells against H₂O₂-induced cell death through PI3K-Akt/GSK-3 β pathway and suppression of NF-kappa β -cytokines. *Drug Des Devel Ther*, 8, 1765-80 (2014)
116. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: mTOR: on target for novel therapeutic strategies in the nervous system. *Trends Mol Med*, 19(1), 51-60 (2013)
DOI: 10.1016/j.molmed.2012.11.001
 117. H. E. Moon, K. Byun, H. W. Park, J. H. Kim, J. Hur, J. S. Park, J. K. Jun, H. S. Kim, S. L. Paek, I. K. Kim, J. H. Hwang, J. W. Kim, D. G. Kim, Y. C. Sung, G. Y. Koh, C. W. Song, B. Lee and S. H. Paek: COMP-Ang1 Potentiates EPC Treatment of Ischemic Brain Injury by Enhancing Angiogenesis Through Activating AKT-mTOR Pathway and Promoting Vascular Migration Through Activating Tie2-FAK Pathway. *Exp Neurol*, 24(1), 55-70 (2015)
DOI: 10.5607/en.2015.24.1.55
 118. J. Romine, X. Gao, X. M. Xu, K. F. So and J. Chen: The proliferation of amplifying neural progenitor cells is impaired in the aging brain and restored by the mTOR pathway activation. *Neurobiol Aging*, 36(4), 1716-26 (2015)
DOI: 10.1016/j.neurobiolaging.2015.01.003
 119. N. S. Rozas, J. B. Redell, J. McKenna, 3rd, A. N. Moore, M. J. Gambello and P. K. Dash: Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation. *Biochem Biophys Res Commun*, 457(4), 635-9 (2015)
DOI: 10.1016/j.bbrc.2015.01.039
 120. X. Zhong, R. Lin, Z. Li, J. Mao and L. Chen: Effects of Salidroside on Cobalt Chloride-Induced Hypoxia Damage and mTOR Signaling Repression in PC12 Cells. *Biol Pharm Bull*, 37(7), 1199-206 (2014)
DOI: 10.1248/bpb.b14-00100
 121. S. Lanfranconi, F. Locatelli, S. Corti, L. Candelise, G. P. Comi, P. L. Baron, S. Strazzer, N. Bresolin and A. Bersano: Growth factors in ischemic stroke. *J Cell Mol Med*, 15(8), 1645-87 (2011)
DOI: 10.1111/j.1582-4934.2009.00987.x
 122. K. Maiese: Programming apoptosis and autophagy with novel approaches for diabetes mellitus. *Curr Neurovasc Res*, 12(2), 173-88 (2015)
DOI: 10.2174/1567202612666150305110929
 123. K. Maiese and L. Boccone: Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C. *J Cereb Blood Flow Metab*, 15(3), 440-9 (1995)
DOI: 10.1038/jcbfm.1995.55
 124. D. Mittal, A. Ali, S. Md, S. Baboota, J. K. Sahni and J. Ali: Insights into direct nose to brain delivery: current status and future perspective. *Drug Deliv*, 21(2), 75-86 (2014)
DOI: 10.3109/10717544.2013.838713
 125. S. S. Newton, N. M. Fournier and R. S. Duman: Vascular growth factors in neuropsychiatry. *Cell Mol Life Sci*, 70(10), 1739-52 (2013)
DOI: 10.1007/s00018-013-1281-9
 126. K. Maiese, F. Li and Z. Z. Chong: New avenues of exploration for erythropoietin. *Jama*, 293(1), 90-5 (2005)
DOI: 10.1001/jama.293.1.90
 127. N. Imai, A. Kawamura, M. Higuchi, M. Oh-eda, T. Orita, T. Kawaguchi and N. Ochi: Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. *J Biochem (Tokyo)*, 107(3), 352-9. (1990)
 128. R. Castaneda-Arellano, C. Beas-Zarate, A. I. Feria-Velasco, E. W. Bitar-Alatorre and M. C. Rivera-Cervantes: From neurogenesis to neuroprotection in the epilepsy: signalling by erythropoietin. *Front Biosci (Landmark Ed)*, 19, 1445-55 (2014)
DOI: 10.2741/4295
 129. K. Maiese, Z. Z. Chong and Y. C. Shang: Raves and risks for erythropoietin. *Cytokine Growth Factor Rev*, 19(2), 145-155 (2008)
DOI: 10.1016/j.cytogfr.2008.01.004
 130. L. Wang, L. Di and C. T. Noguchi: Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. *Int J Biol Sci*, 10(8), 921-39 (2014)
DOI: 10.7150/ijbs.9518
 131. Y. Zhang, L. Wang, S. Dey, M. Alnaeeli, S. Suresh, H. Rogers, R. Teng and C. T. Noguchi: Erythropoietin action in stress response, tissue maintenance and metabolism. *Int J Mol Sci*, 15(6), 10296-333 (2014)
DOI: 10.3390/ijms150610296
 132. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Erythropoietin: new directions for

- the nervous system. *Int J Mol Sci*, 13(9), 11102-29 (2012)
DOI: 10.3390/ijms130911102
133. K. Maiese, Z. Z. Chong, F. Li and Y. C. Shang: Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. *Prog Neurobiol*, 85(2), 194-213 (2008)
DOI: 10.1016/j.pneurobio.2008.02.002
 134. C. Bernard: Remarques sur le sécrétion du sucre dans la foie, faites à l'occasion de la communication de M. Lehman. *Comptes rendus Academies de Sciences*, 40, 589-592 (1855)
 135. P. Carnot and C. DeFlandre: Sur l'activité hemopoietique de serum au cours de la regeneration du sang. *C R Acad Sci (Paris)* 143, 384-386 (1906)
 136. A. J. Erslev: In vitro production of erythropoietin by kidneys perfused with a serum-free solution. *Blood*, 44(1), 77-85 (1974)
 137. C. Gibelli: Über den wert des serums anamisch gemachten tiere bei der regeneration des blutes. *Arch Exp Pathol Pharmacol*, 65, 284-302 (1911)
DOI: 10.1007/BF01841822
 138. G. Sandor: Über die blutbildende wirkung des serums von tieren, die in verdünnter luft gehalten wuren. *Z Gesante Exp Med*, 82, 633-646 (1932)
DOI: 10.1007/BF02598945
 139. K. Jacobs, C. Shoemaker, R. Rudersdorf, S. D. Neill, R. J. Kaufman, A. Mufson, J. Seehra, S. S. Jones, R. Hewick, E. F. Fritsch, M. Kawakita, T. Shimizu and T. Miyake: Isolation and characterization of genomic and cDNA clones of human erythropoietin. *Nature*, 313(6005), 806-10. (1985)
DOI: 10.1038/313806a0
 140. F. K. Lin, S. Suggs, C. H. Lin, J. K. Browne, R. Smalling, J. C. Egrie, K. K. Chen, G. M. Fox, F. Martin, Z. Stabinsky, S. Badrawi, P.-H. Lai and E. Goldwasser: Cloning and expression of the human erythropoietin gene. *Proc Natl Acad Sci U S A*, 82(22), 7580-4 (1985)
DOI: 10.1073/pnas.82.22.7580
 141. F. Li, Z. Z. Chong and K. Maiese: Erythropoietin on a Tightrope: Balancing Neuronal and Vascular Protection between Intrinsic and Extrinsic Pathways. *Neurosignals*, 13(6), 265-89 (2004)
DOI: 10.1159/000081963
 142. A. Palazzuoli, G. Ruocco, M. Pellegrini, C. De Gori, G. Del Castillo, N. Giordano and R. Nuti: The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. *Ther Clin Risk Manag*, 10, 641-50 (2014)
DOI: 10.2147/TCRM.S61551
 143. E. M. Moore, R. Bellomo and A. D. Nichol: Erythropoietin as a novel brain and kidney protective agent. *Anaesth Intensive Care*, 39(3), 356-72 (2011)
 144. C. Caprara and C. Grimm: From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. *Prog Retin Eye Res*, 31(1), 89-119 (2012)
DOI: 10.1016/j.preteyeres.2011.11.003
 145. Z. Z. Chong, J. Q. Kang and K. Maiese: Angiogenesis and plasticity: role of erythropoietin in vascular systems. *J Hematother Stem Cell Res*, 11(6), 863-71 (2002)
DOI: 10.1089/152581602321080529
 146. S. Kato, M. Aoyama, H. Kakita, H. Hida, I. Kato, T. Ito, T. Goto, M. H. Hussein, K. Sawamoto, H. Togari and K. Asai: Endogenous erythropoietin from astrocyte protects the oligodendrocyte precursor cell against hypoxic and reoxygenation injury. *J Neurosci Res*, 89(10), 1566-74 (2011)
DOI: 10.1002/jnr.22702
 147. K. Maiese, F. Li and Z. Z. Chong: Erythropoietin in the brain: can the promise to protect be fulfilled? *Trends Pharmacol Sci*, 25(11), 577-583 (2004)
DOI: 10.1016/j.tips.2004.09.006
 148. S. B. Krantz: Erythropoietin. *Blood*, 77(3), 419-34. (1991)
 149. K. Maiese, Z. Z. Chong, J. Hou and Y. C. Shang: Erythropoietin and oxidative stress. *Curr Neurovasc Res*, 5(2), 125-42 (2008)
DOI: 10.2174/156720208784310231
 150. E. Tsuda, G. Kawanishi, M. Ueda, S. Masuda and R. Sasaki: The role of carbohydrate in recombinant human erythropoietin. *Eur J Biochem*, 188(2), 405-11. (1990)
DOI: 10.1111/j.1432-1033.1990.tb15417.x
 151. E. Uchida, K. Morimoto, N. Kawasaki, Y. Izaki, A. Abdu Said and T. Hayakawa: Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human

- erythropoietin. *Free Radic Res*, 27(3), 311-23. (1997)
DOI: 10.3109/10715769709065769
152. T. Toyoda, T. Itai, T. Arakawa, K. H. Aoki and H. Yamaguchi: Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. *J Biochem (Tokyo)*, 128(5), 731-7. (2000)
DOI: 10.1093/oxfordjournals.jbchem.a022809
 153. F. F. Wang, C. K. Kung and E. Goldwasser: Some chemical properties of human erythropoietin. *Endocrinology*, 116(6), 2286-92. (1985)
DOI: 10.1210/endo-116-6-2286
 154. K. Reissmann: Studies on the mechanism of erythropoietin stimulation in parabiotic rats during hypoxia. *Blood*, 5, 347-380 (1950)
 155. K. Maiese: Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. *Biomed Pharmacother*, 62(4), 218-232 (2008)
DOI: 10.1016/j.biopha.2008.01.009
 156. K. Maiese: Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. *Neural Regen Res*, 10(4), 518-528 (2015)
DOI: 10.4103/1673-5374.155427
 157. A. Guven Bagla, E. Ercan, H. F. Asgun, M. Ickin, F. Ercan, O. Yavuz, S. Bagla and A. Kaplan: Experimental acute myocardial infarction in rats: HIF-1 α , caspase-3, erythropoietin and erythropoietin receptor expression and the cardioprotective effects of two different erythropoietin doses. *Acta Histochem*, 115(7), 658-68 (2013)
DOI: 10.1016/j.acthis.2013.01.005
 158. K. Nishimura, M. Tokida, H. Katsuyama, H. Nakagawa and S. Matsuo: The effect of hemin-induced oxidative stress on erythropoietin production in HepG2 cells. *Cell Biol Int* (2014)
DOI: 10.1002/cbin.10329
 159. A. A. Ali, J. A. Coulter, C. H. Ogle, M. M. Migaud, D. G. Hirst, T. Robson and H. O. McCarthy: The contribution of N(2)O(3) to the cytotoxicity of the nitric oxide donor DETA/NO: an emerging role for S-nitrosylation. *Biosci Rep*, 33(2) (2013)
DOI: 10.1042/BSR20120120
 160. A. Deng, M. A. Arndt, J. Satriano, P. Singh, T. Rieg, S. Thomson, T. Tang and R. C. Blantz: Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade. *Am J Physiol Renal Physiol*, 299(6), F1365-73 (2010)
DOI: 10.1152/ajprenal.00153.2010
 161. N. Singh, G. Sharma, V. Mishra and R. Raghubir: Hypoxia Inducible Factor-1: Its Potential Role In Cerebral Ischemia. *Cell Mol Neurobiol* (2012)
DOI: 10.1007/s10571-012-9803-9
 162. K. Teramo, M. A. Kari, M. Eronen, H. Markkanen and V. Hiilesmaa: High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies. *Diabetologia*, 47(10), 1695-703 (2004)
DOI: 10.1007/s00125-004-1515-3
 163. S. J. Korzeniewski, E. Allred, J. W. Logan, R. N. Fichorova, S. Engelke, K. C. Kuban, T. M. O'Shea, N. Paneth, M. Holm, O. Dammann and A. Leviton: Elevated endogenous erythropoietin concentrations are associated with increased risk of brain damage in extremely preterm neonates. *PLoS One*, 10(3), e0115083 (2015)
DOI: 10.1371/journal.pone.0115083
 164. S. Masuda, M. Chikuma and R. Sasaki: Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. *Brain Res*, 746(1-2), 63-70 (1997)
DOI: 10.1016/S0006-8993(96)01186-9
 165. A. Symeonidis, A. Kouraklis-Symeonidis, A. Psiroyiannis, M. Leotsinidis, V. Kyriazopoulou, P. Vassilakos, A. Vagenakis and N. Zoumbos: Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. *Ann Hematol*, 85(2), 79-85 (2006)
DOI: 10.1007/s00277-005-1102-9
 166. C. F. Tsai, Y. H. Kuo, W. L. Yeh, C. Y. Wu, H. Y. Lin, S. W. Lai, Y. S. Liu, L. H. Wu, J. K. Lu and D. Y. Lu: Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells. *Int J Mol Sci*, 16(3), 5572-5589 (2015)
DOI: 10.3390/ijms16035572
 167. N. Diez-Padrisa, R. Aguilar, S. Machevo, L. Morais, T. Nhampossa, C. O'Callaghan-Gordo, D. Nhalungo, C. Menendez, A. Roca, P. L. Alonso and Q. Bassat: Erythropoietin

- levels are not independently associated with malaria-attributable severe disease in mozambican children. *PLoS ONE*, 6(8), e24090 (2011)
DOI: 10.1371/journal.pone.0024090
168. C. Stoppe, M. Coburn, A. Fahlenkamp, J. Ney, S. Kraemer, R. Rossaint and A. Goetzenich: Elevated serum concentrations of erythropoietin after xenon anaesthesia in cardiac surgery: secondary analysis of a randomized controlled trial. *Br J Anaesth*, 114(4), 701-3 (2015)
DOI: 10.1093/bja/aev060
 169. N. Kaushal, S. Hegde, J. Lumadue, R. F. Paulson and K. S. Prabhu: The regulation of erythropoiesis by selenium in mice. *Antioxid Redox Signal*, 14(8), 1403-12 (2011)
DOI: 10.1089/ars.2010.3323
 170. Z. Z. Chong, J. Q. Kang and K. Maiese: Erythropoietin: cytoprotection in vascular and neuronal cells. *Curr Drug Targets Cardiovasc Haematol Disord*, 3(2), 141-54 (2003)
DOI: 10.2174/1568006033481483
 171. C. L. Li, J. Jiang, Y. Q. Fan, G. S. Fu, J. A. Wang and W. M. Fan: Knockout of the tumor necrosis factor α receptor 1 gene can up-regulate erythropoietin receptor during myocardial ischemia-reperfusion injury in mice. *Chin Med J (Engl)*, 122(5), 566-70 (2009)
 172. Z. Z. Chong, J. Q. Kang and K. Maiese: Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. *J Cereb Blood Flow Metab*, 22(5), 503-14 (2002)
DOI: 10.1097/00004647-200205000-00001
 173. Z. Z. Chong, F. Li and K. Maiese: Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. *Histol Histopathol*, 20(1), 299-315 (2005)
 174. Z. Z. Chong, Y. C. Shang, S. Wang and K. Maiese: A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. *Future Neurol*, 7(6), 733-748 (2012)
DOI: 10.2217/fnl.12.72
 175. Y. Fong, Y. C. Lin, C. Y. Wu, H. M. Wang, L. L. Lin, H. L. Chou, Y. N. Teng, S. S. Yuan and C. C. Chiu: The antiproliferative and apoptotic effects of sirtinol, a sirtuin inhibitor on human lung cancer cells by modulating Akt/beta-catenin-Foxo3a axis. *ScientificWorldJournal*, 2014, 937051 (2014)
DOI: 10.1155/2014/937051
 176. S. Al Sweidi, M. G. Sanchez, M. Bourque, M. Morissette, D. Dluzen and T. Di Paolo: Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. *J Neuroendocrinol*, 24(1), 48-61 (2012)
DOI: 10.1111/j.1365-2826.2011.02193.x
 177. K. K. Ambacher, K. B. Pitzul, M. Karajgikar, A. Hamilton, S. S. Ferguson and S. P. Cregan: The JNK- and AKT/GSK3beta- Signaling Pathways Converge to Regulate Puma Induction and Neuronal Apoptosis Induced by Trophic Factor Deprivation. *PLoS ONE*, 7(10), e46885 (2012)
DOI: 10.1371/journal.pone.0046885
 178. R. M. Uranga, S. Katz and G. A. Salvador: Enhanced phosphatidylinositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hippocampal neurons exposed to iron-induced oxidative stress. *J Biol Chem*, 288(27), 19773-84 (2013)
DOI: 10.1074/jbc.M113.457622
 179. X. Zhou, L. Wang, M. Wang, L. Xu, L. Yu, T. Fang and M. Wu: Emodin-induced microglial apoptosis is associated with TRB3 induction. *Immunopharmacol Immunotoxicol*, 33(4), 594-602 (2011)
DOI: 10.3109/08923973.2010.549135
 180. J. Branchu, O. Biondi, F. Chali, T. Collin, F. Leroy, K. Mamchaoui, J. Makoukji, C. Pariset, P. Lopes, C. Massaad, C. Chanoine and F. Charbonnier: Shift from extracellular signal-regulated kinase to AKT/cAMP response element-binding protein pathway increases survival-motor-neuron expression in spinal-muscular-atrophy-like mice and patient cells. *J Neurosci*, 33(10), 4280-94 (2013)
DOI: 10.1523/JNEUROSCI.2728-12.2013
 181. B. Chen, J. A. Van Winkle, P. D. Lyden, J. H. Brown and N. H. Purcell: PHLPP1 gene deletion protects the brain from ischemic injury. *J Cereb Blood Flow Metab*, 33(2), 196-204 (2013)
DOI: 10.1038/jcbfm.2012.150
 182. L. Bing, J. Wu, J. Zhang, Y. Chen, Z. Hong and H. Zu: DHT Inhibits the Abeta25-35-Induced Apoptosis by Regulation of Seladin-1, Survivin, XIAP, bax, and bcl-xl Expression Through a Rapid PI3-K/Akt

- Signaling in C6 Glial Cell Lines. *Neurochem Res* (2014)
183. Z. Z. Chong, F. Li and K. Maiese: Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. *Cell Signal*, 19(6), 1150-62 (2007)
DOI: 10.1016/j.cellsig.2006.12.009
 184. V. Echeverria, R. Zeitlin, S. Burgess, S. Patel, A. Barman, G. Thakur, M. Mamcarz, L. Wang, D. B. Sattelle, D. A. Kirschner, T. Mori, R. M. Leblanc, R. Prabhakar and G. W. Arendash: Cytinine Reduces Amyloid-beta Aggregation and Improves Memory in Alzheimer's Disease Mice. *J Alzheimers Dis* (2011)
 185. J. Liang, L. Liu and D. Xing: Photobiomodulation by low-power laser irradiation attenuates Abeta-induced cell apoptosis through the Akt/GSK3beta/beta-catenin pathway. *Free Radic Biol Med*, 53(7), 1459-67 (2012)
DOI: 10.1016/j.freeradbiomed.2012.08.003
 186. Y. C. Shang, Z. Z. Chong, S. Wang and K. Maiese: Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. *Aging (Albany NY)*, 4(3), 187-201 (2012)
 187. Y. C. Shang, Z. Z. Chong, S. Wang and K. Maiese: Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia. *Curr Neurovasc Res*, 10(1), 29-38 (2013)
DOI: 10.2174/156720213804806007
 188. Y. Wang, Y. X. Wang, T. Liu, P. Y. Law, H. H. Loh, Y. Qiu and H. Z. Chen: mu-Opioid Receptor Attenuates Abeta Oligomers-Induced Neurotoxicity Through mTOR Signaling. *CNS Neurosci Ther* (2014)
 189. Z. Xue, Y. Guo, S. Zhang, L. Huang, Y. He, R. Fang and Y. Fang: Beta-asarone attenuates amyloid beta-induced autophagy via Akt/mTOR pathway in PC12 cells. *Eur J Pharmacol*, 741, 195-204 (2014)
DOI: 10.1016/j.ejphar.2014.08.006
 190. S. Zara, M. De Colli, M. Rapino, S. Pacella, C. Nasuti, P. Sozio, A. Di Stefano and A. Cataldi: Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model. *Gerontology*, 59(3), 250-60 (2013)
DOI: 10.1159/000346445
 191. K. W. Zeng, X. M. Wang, H. Ko, H. C. Kwon, J. W. Cha and H. O. Yang: Hyperoside protects primary rat cortical neurons from neurotoxicity induced by amyloid beta-protein via the PI3K/Akt/Bad/Bcl(XL)-regulated mitochondrial apoptotic pathway. *Eur J Pharmacol*, 672(1-3), 45-55 (2011)
DOI: 10.1016/j.ejphar.2011.09.177
 192. J. Zhang, X. Feng, J. Wu, H. Xu, G. Li, D. Zhu, Q. Yue, H. Liu, Y. Zhang, D. Sun, H. Wang and J. Sun: Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by beta-amyloid through activation of SIRT1/Akt1 pathway. *Biofactors*, 40(2), 258-267 (2013)
DOI: 10.1002/biof.1149
 193. Z. Zhu, J. Yan, W. Jiang, X. G. Yao, J. Chen, L. Chen, C. Li, L. Hu, H. Jiang and X. Shen: Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance. *J Neurosci*, 33(32), 13138-49 (2013)
DOI: 10.1523/JNEUROSCI.4790-12.2013
 194. Z. Z. Chong and K. Maiese: Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. *Br J Pharmacol*, 150(7), 839-50 (2007)
DOI: 10.1038/sj.bjp.0707161
 195. Y. F. Ji, L. Zhou, Y. J. Xie, S. M. Xu, J. Zhu, P. Teng, C. Y. Shao, Y. Wang, J. H. Luo and Y. Shen: Upregulation of glutamate transporter GLT-1 by mTOR-Akt-NF-small ka, CyrillicB cascade in astrocytic oxygen-glucose deprivation. *Glia*, 61(12), 1959-75 (2013)
DOI: 10.1002/glia.22566
 196. F. Li, Z. Z. Chong and K. Maiese: Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. *Curr Neurovasc Res*, 3(3), 187-201 (2006)
DOI: 10.2174/156720206778018758
 197. S. Wang, Z. Z. Chong, Y. C. Shang and K. Maiese: Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving

- Bad, Bax, Bim, and Bcl-xL. *Curr Neurovasc Res*, 9(1), 20-31 (2012)
DOI: 10.2174/156720212799297137
198. F. Zhang, T. Ding, L. Yu, Y. Zhong, H. Dai and M. Yan: Dexmedetomidine protects against oxygen-glucose deprivation-induced injury through the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells. *J Pharm Pharmacol*, 64(1), 120-7 (2012)
DOI: 10.1111/j.2042-7158.2011.01382.x
 199. Z. Z. Chong, J. Q. Kang and K. Maiese: Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. *Circulation*, 106(23), 2973-9 (2002)
DOI: 10.1161/01.CIR.0000039103.58920.1F
 200. Z. Rong, R. Pan, Y. Xu, C. Zhang, Y. Cao and D. Liu: Hesperidin pretreatment protects hypoxia-ischemic brain injury in neonatal rat. *Neuroscience*, 255, 292-9 (2013)
DOI: 10.1016/j.neuroscience.2013.09.030
 201. B. N. Seo, J. M. Ryu, S. P. Yun, J. H. Jeon, S. S. Park, K. B. Oh, J. K. Park and H. J. Han: Delphinidin prevents hypoxia-induced mouse embryonic stem cell apoptosis through reduction of intracellular reactive oxygen species-mediated activation of JNK and NF-kappaB, and Akt inhibition. *Apoptosis*, 18(7), 811-24 (2013)
DOI: 10.1007/s10495-013-0838-2
 202. J. Su, Y. Tang, H. Zhou, L. Liu and Q. Dong: Tissue kallikrein protects neurons from hypoxia/reoxygenation-induced cell injury through Homer1b/c. *Cell Signal*, 24(11), 2205-15 (2012)
DOI: 10.1016/j.cellsig.2012.04.021
 203. S. Busch, A. Kannt, M. Kolibabka, A. Schlotterer, Q. Wang, J. Lin, Y. Feng, S. Hoffmann, N. Gretz and H. P. Hammes: Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration. *PLoS One*, 9(7), e102013 (2014)
DOI: 10.1371/journal.pone.0102013
 204. Z. Z. Chong, J. Hou, Y. C. Shang, S. Wang and K. Maiese: EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a, GSK-3beta, and beta-Catenin to Foster Vascular Integrity During Experimental Diabetes. *Curr Neurovasc Res*, 8(2), 103-20 (2011)
DOI: 10.2174/156720211795495402
 205. F. Das, N. Dey, B. Venkatesan, B. S. Kasinath, N. Ghosh-Choudhury and G. G. Choudhury: High glucose upregulation of early-onset Parkinson's disease protein DJ-1 integrates the PRAS40/TORC1 axis to mesangial cell hypertrophy. *Cell Signal*, 23(8), 1311-9 (2011)
DOI: 10.1016/j.cellsig.2011.03.012
 206. J. Hou, Z. Z. Chong, Y. C. Shang and K. Maiese: FoxO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. *Mol Cell Endocrinol*, 321(2), 194-206 (2010)
DOI: 10.1016/j.mce.2010.02.037
 207. J. Hou, Z. Z. Chong, Y. C. Shang and K. Maiese: Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. *Curr Neurovasc Res*, 7(2), 95-112 (2010)
DOI: 10.2174/156720210791184899
 208. R. Kimura, M. Okouchi, T. Kato, K. Imaeda, N. Okayama, K. Asai and T. Joh: Epidermal growth factor receptor transactivation is necessary for glucagon-like peptide-1 to protect PC12 cells from apoptosis. *Neuroendocrinology*, 97(4), 300-8 (2013)
DOI: 10.1159/000345529
 209. Z. Y. Chang, M. K. Yeh, C. H. Chiang, Y. H. Chen and D. W. Lu: Erythropoietin protects adult retinal ganglion cells against NMDA-, trophic factor withdrawal-, and TNF-alpha-induced damage. *PLoS One*, 8(1), e55291 (2013)
DOI: 10.1371/journal.pone.0055291
 210. Z. Z. Chong, J. Q. Kang and K. Maiese: Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. *Br J Pharmacol*, 138(6), 1107-1118 (2003)
DOI: 10.1038/sj.bjp.0705161
 211. M. S. Kwon, M. H. Kim, S. H. Kim, K. D. Park, S. H. Yoo, I. U. Oh, S. Pak and Y. J. Seo: Erythropoietin exerts cell protective effect by activating PI3K/Akt and MAPK pathways in C6 Cells. *Neurol Res*, 36(3), 215-23 (2014)
DOI: 10.1179/1743132813Y.0000000284
 212. A. Parvin, R. Pranap, U. Shalini, A. Devendran, J. E. Baker and A. Dhanasekaran: Erythropoietin protects cardiomyocytes from cell death during hypoxia/reperfusion injury through activation of survival signaling

- pathways. *PLoS One*, 9(9), e107453 (2014)
DOI: 10.1371/journal.pone.0107453
213. Y. Yu, S. R. Shiou, Y. Guo, L. Lu, M. Westerhoff, J. Sun, E. O. Petrof and E. C. Claud: Erythropoietin protects epithelial cells from excessive autophagy and apoptosis in experimental neonatal necrotizing enterocolitis. *PLoS One*, 8(7), e69620 (2013)
DOI: 10.1371/journal.pone.0069620
 214. J. Kang, J. Y. Yun, J. Hur, J. A. Kang, J. I. Choi, S. B. Ko, J. Lee, J. Y. Kim, I. C. Hwang, Y. B. Park and H. S. Kim: Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. *Cardiovasc Res*, 104(1), 171-82 (2014)
DOI: 10.1093/cvr/cvu180
 215. Z. Z. Chong, S. H. Lin, J. Q. Kang and K. Maiese: Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. *J Neurosci Res*, 71(5), 659-69 (2003)
DOI: 10.1002/jnr.10528
 216. W. Fu, X. Liao, J. Ruan, X. Li, L. Chen, B. Wang, K. Wang and J. Zhou: Recombinant human erythropoietin preconditioning attenuates liver ischemia reperfusion injury through the phosphatidylinositol-3 kinase/AKT/endothelial nitric oxide synthase pathway. *J Surg Res*, 183(2), 876-84 (2013)
DOI: 10.1016/j.jss.2013.01.044
 217. R. Ma, N. Xiong, C. Huang, Q. Tang, B. Hu, J. Xiang and G. Li: Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. *Neuropharmacology*, 56(6-7), 1027-34 (2009)
DOI: 10.1016/j.neuropharm.2009.02.006
 218. T. Maurice, M. H. Mustafa, C. Desrumaux, E. Keller, G. Naert, C. G.-B. M. de la, Y. Rodriguez Cruz and J. C. Garcia Rodriguez: Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(-)(3)(5) non-transgenic mouse model of Alzheimer's disease. *J Psychopharmacol*, 27(11), 1044-57 (2013)
DOI: 10.1177/0269881113494939
 219. Z. K. Sun, H. Q. Yang, J. Pan, H. Zhen, Z. Q. Wang, S. D. Chen and J. Q. Ding: Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid. *J Neurosci Res*, 86(13), 3018-27 (2008)
DOI: 10.1002/jnr.21745
 220. Y. Bennis, G. Sarlon-Bartoli, B. Guillet, L. Lucas, L. Pellegrini, L. Velly, M. Blot-Chabaud, F. Dignat-Georges, F. Sabatier and P. Pisano: Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. *J Thromb Haemost*, 10(9), 1914-28 (2012)
DOI: 10.1111/j.1538-7836.2012.04835.x
 221. J. Hou, S. Wang, Y. C. Shang, Z. Z. Chong and K. Maiese: Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress. *Curr Neurovasc Res*, 8(3), 220-35 (2011)
DOI: 10.2174/156720211796558069
 222. A. I. Khan, S. M. Coldewey, N. S. Patel, M. Rogazzo, M. Collino, M. M. Yaqoob, P. Radermacher, A. Kapoor and C. Thiernemann: Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the beta-common receptor. *Dis Model Mech*, 6(4), 1021-30 (2013)
DOI: 10.1242/dmm.011908
 223. Y. Nakazawa, T. Nishino, Y. Obata, M. Nakazawa, A. Furusu, K. Abe, M. Miyazaki, T. Koji and S. Kohn: Recombinant human erythropoietin attenuates renal tubulointerstitial injury in murine adriamycin-induced nephropathy. *J Nephrol*, 26(3), 527-33 (2013)
DOI: 10.5301/jn.5000178
 224. K. H. Su, S. K. Shyue, Y. R. Kou, L. C. Ching, A. N. Chiang, Y. B. Yu, C. Y. Chen, C. C. Pan and T. S. Lee: beta Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. *J Cell Physiol*, 226(12), 3330-9 (2011)
DOI: 10.1002/jcp.22678
 225. H. Toba, Y. Kojima, J. Wang, K. Noda, W. Tian, M. Kobara and T. Nakata: Erythropoietin attenuated vascular dysfunction and inflammation by inhibiting NADPH oxidase-derived superoxide production in nitric oxide synthase-inhibited hypertensive rat aorta. *Eur J Pharmacol*, 691(1-3), 190-7 (2012)
DOI: 10.1016/j.ejphar.2012.07.018
 226. H. Toba, N. Sawai, M. Morishita, S. Murata, M. Yoshida, K. Nakashima, Y. Morita, M.

- Kobara and T. Nakata: Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. *Eur J Pharmacol*, 612(1-3), 106-14 (2009)
DOI: 10.1016/j.ejphar.2009.03.065
227. Y. C. Shang, Z. Z. Chong, S. Wang and K. Maiese: Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia. *Curr Neurovasc Res*, 8(4), 270-285 (2011)
DOI: 10.2174/156720211798120990
 228. J. Shen, Y. Wu, J. Y. Xu, J. Zhang, S. H. Sinclair, M. Yanoff, G. Xu, W. Li and G. T. Xu: ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. *Invest Ophthalmol Vis Sci*, 51(1), 35-46 (2010)
DOI: 10.1167/iops.09-3544
 229. G. B. Wang, Y. L. Ni, X. P. Zhou and W. F. Zhang: The AKT/mTOR pathway mediates neuronal protective effects of erythropoietin in sepsis. *Mol Cell Biochem*, 385(1-2), 125-32 (2014)
DOI: 10.1007/s11010-013-1821-5
 230. K. Maiese: Forkhead Transcription Factors: Vital Elements in Biology and Medicine. *Advances in Experimental Medicine and Biology, Springer Science and Business Media*, 665 (2010)
 231. W. H. Biggs, 3rd, W. K. Cavenee and K. C. Arden: Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. *Mamm Genome*, 12(6), 416-25 (2001)
DOI: 10.1007/s003350020002
 232. H. Huang and D. J. Tindall: Dynamic FoxO transcription factors. *J Cell Sci*, 120(Pt 15), 2479-87 (2007)
DOI: 10.1242/jcs.001222
 233. K. Maiese, Z. Z. Chong, Y. C. Shang and J. Hou: FoxO proteins: cunning concepts and considerations for the cardiovascular system. *Clin Sci (Lond)*, 116(3), 191-203 (2009)
DOI: 10.1042/CS20080113
 234. K. Maiese, Z. Z. Chong and Y. C. Shang: "Sly as a FOXO": New paths with Forkhead signaling in the brain. *Curr Neurovasc Res*, 4(4), 295-302 (2007)
DOI: 10.2174/156720207782446306
 235. D. L. Trinh, D. W. Scott, R. D. Morin, M. Mendez-Lago, J. An, S. J. Jones, A. J. Mungall, Y. Zhao, J. Schein, C. Steidl, J. M. Connors, R. D. Gascoyne and M. A. Marra: Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. *Blood*, 121(18), 3666-74 (2013)
DOI: 10.1182/blood-2013-01-479865
 236. S. Carbajo-Pescador, J. L. Mauriz, A. Garcia-Palomo and J. Gonzalez-Gallego: FoxO proteins: regulation and molecular targets in liver cancer. *Curr Med Chem*, 21(10), 1231-46 (2014)
DOI: 10.2174/0929867321666131228205703
 237. M. E. Chamorro, S. D. Wenker, D. M. Vota, D. C. Vittori and A. B. Nesse: Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative. *Biochim Biophys Acta*, 1833(8), 1960-8 (2013)
DOI: 10.1016/j.bbamcr.2013.04.006
 238. P. Scodelaro Bilbao and R. Boland: Extracellular ATP regulates FoxO family of transcription factors and cell cycle progression through PI3K/Akt in MCF-7 cells. *Biochim Biophys Acta*, 1830(10), 4456-69 (2013)
DOI: 10.1016/j.bbagen.2013.05.034
 239. G. Z. Tao, N. Lehwald, K. Y. Jang, J. Baek, B. Xu, M. B. Omary and K. G. Sylvester: Wnt/ beta-catenin signaling protects mouse liver against oxidative stress-induced apoptosis through the inhibition of forkhead transcription factor FoxO3. *J Biol Chem*, 288(24), 17214-24 (2013)
DOI: 10.1074/jbc.M112.445965
 240. C. P. Wong, T. Kaneda, A. H. Hadi and H. Morita: Ceramicine B, a limonoid with anti-lipid droplets accumulation activity from *Chisocheton ceramicus*. *J Nat Med*, 68(1), 22-30 (2014)
DOI: 10.1007/s11418-013-0755-2
 241. H. Matsuzaki, H. Daitoku, M. Hatta, H. Aoyama, K. Yoshimochi and A. Fukamizu: Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. *Proc Natl Acad Sci U S A*, 102(32), 11278-83 (2005)
DOI: 10.1073/pnas.0502738102
 242. G. Xu, J. Liu, K. Yoshimoto, G. Chen, T. Iwata, N. Mizusawa, Z. Duan, C. Wan and J. Jiang: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces expression of p27(kip1) and FoxO3a in female rat cerebral cortex and PC12 cells.

- Toxicol Lett*, 226(3), 294-302 (2014)
DOI: 10.1016/j.toxlet.2014.02.019
243. Y. C. Shang, Z. Z. Chong, J. Hou and K. Maiese: Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. *Cell Signal*, 22(9), 1317-29 (2010)
DOI: 10.1016/j.cellsig.2010.04.009
 244. A. Wilk, K. Urbanska, S. Yang, J. Y. Wang, S. Amini, L. Del Valle, F. Peruzzi, L. Meggs and K. Reiss: Insulin-like growth factor-I-forkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factor-alpha-mediated neuronal damage: implications for human immunodeficiency virus encephalitis. *J Neurosci Res*, 89(2), 183-98 (2011)
DOI: 10.1002/jnr.22542
 245. N. Hariharan, Y. Maejima, J. Nakae, J. Paik, R. A. Depinho and J. Sadoshima: Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating Starvation-Induced Autophagy in Cardiac Myocytes. *Circ Res*, 107(12), 1470-82 (2010)
DOI: 10.1161/CIRCRESAHA.110.227371
 246. S. Iyer, L. Han, S. M. Bartell, H. N. Kim, I. Gubrij, R. de Cabo, C. A. O'Brien, S. C. Manolagas and M. Almeida: Sirtuin1 (Sirt1) promotes cortical bone formation by preventing beta-catenin sequestration by FoxO transcription factors in osteoblast progenitors. *J Biol Chem*, 289(35), 24069-78 (2014)
DOI: 10.1074/jbc.M114.561803
 247. J. Shi, N. Yin, L. L. Xuan, C. S. Yao, A. M. Meng and Q. Hou: Vam3, a derivative of resveratrol, attenuates cigarette smoke-induced autophagy. *Acta Pharmacol Sin*, 33(7), 888-96 (2012)
DOI: 10.1038/aps.2012.73
 248. Y. Akasaki, O. Alvarez-Garcia, M. Saito, B. Carames, Y. Iwamoto and M. K. Lotz: FOXO transcription factors support oxidative stress resistance in human chondrocytes. *Arthritis Rheumatol*, 66(12), 3349-3358 (2014)
DOI: 10.1002/art.38868
 249. V. Balan, G. S. Miller, L. Kaplun, K. Balan, Z. Z. Chong, F. Li, A. Kaplun, M. F. VanBerkum, R. Arking, D. C. Freeman, K. Maiese and G. Tzivion: Life span extension and neuronal cell protection by Drosophila nicotinamidase. *J Biol Chem*, 283(41), 27810-9 (2008)
DOI: 10.1074/jbc.M804681200
 250. Z. Z. Chong, S. Wang, Y. C. Shang and K. Maiese: Targeting cardiovascular disease with novel SIRT1 pathways. *Future Cardiol*, 8(1), 89-100 (2012)
DOI: 10.2217/fca.11.76
 251. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Translating cell survival and cell longevity into treatment strategies with SIRT1. *Rom J Morphol Embryol*, 52(4), 1173-85 (2011)
 252. A. F. Paraiso, K. L. Mendes and S. H. Santos: Brain activation of SIRT1: role in neuropathology. *Mol Neurobiol*, 48(3), 681-9 (2013)
DOI: 10.1007/s12035-013-8459-x
 253. W. Wang, C. Yan, J. Zhang, R. Lin, Q. Lin, L. Yang, F. Ren, J. Zhang, M. Ji and Y. Li: SIRT1 inhibits TNF-alpha-induced apoptosis of vascular adventitial fibroblasts partly through the deacetylation of FoxO1. *Apoptosis*, 18(6), 689-701 (2013)
DOI: 10.1007/s10495-013-0833-7
 254. G. Arunachalam, S. M. Samuel, I. Marei, H. Ding and C. R. Triggle: Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. *Br J Pharmacol*, 171(2), 523-35 (2014)
DOI: 10.1111/bph.12496
 255. N. D'Onofrio, M. Vitiello, R. Casale, L. Servillo, A. Giovane and M. L. Balestrieri: Sirtuins in vascular diseases: Emerging roles and therapeutic potential. *Biochim Biophys Acta*, 1852(7), 1311-1322 (2015)
DOI: 10.1016/j.bbdis.2015.03.001
 256. Y. Liu, H. Chen and D. Liu: Mechanistic perspectives of calorie restriction on vascular homeostasis. *Sci China Life Sci*, 57(8), 742-754 (2014)
DOI: 10.1007/s11427-014-4709-z
 257. S. Xu, P. Bai, P. J. Little and P. Liu: Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. *Med Res Rev*, 34(3), 644-75 (2014)
DOI: 10.1002/med.21300
 258. G. Favero, L. Franceschetti, L. F. Rodella and R. Rezzani: Sirtuins, aging, and cardiovascular risks. *Age (Dordr)*, 37(4), 9804 (2015)
DOI: 10.1007/s11357-015-9804-y

259. N. Ferrara, B. Rinaldi, G. Corbi, V. Conti, P. Stiuso, S. Boccuti, G. Rengo, F. Rossi and A. Filippelli: Exercise Training Promotes SIRT1 Activity in Aged Rats. *Rejuvenation Res*, 11(1), 139-150 (2008)
DOI: 10.1089/rej.2007.0576
260. R. R. Alcendor, S. Gao, P. Zhai, D. Zablocki, E. Holle, X. Yu, B. Tian, T. Wagner, S. F. Vatner and J. Sadoshima: Sirt1 regulates aging and resistance to oxidative stress in the heart. *Circ Res*, 100(10), 1512-21 (2007)
DOI: 10.1161/01.RES.0000267723.65696.4a
261. S. Xiong, G. Salazar, N. Patrushev and R. W. Alexander: FoxO1 Mediates an Autofeedback Loop Regulating SIRT1 Expression. *J Biol Chem*, 286(7), 5289-99 (2011)
DOI: 10.1074/jbc.M110.163667
262. E. H. Hong, S. J. Lee, J. S. Kim, K. H. Lee, H. D. Um, J. H. Kim, S. J. Kim, J. I. Kim and S. G. Hwang: Ionizing radiation induces cellular senescence of articular chondrocytes via negative regulation of SIRT1 by p38 kinase. *J Biol Chem*, 285(2), 1283-95 (2010)
DOI: 10.1074/jbc.M109.058628
263. Z. Gao, J. Zhang, I. Kheterpal, N. Kennedy, R. J. Davis and J. Ye: Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. *J Biol Chem*, 286(25), 22227-34 (2011)
DOI: 10.1074/jbc.M111.228874
264. T. Kozako, A. Aikawa, T. Shoji, T. Fujimoto, M. Yoshimitsu, S. Shirasawa, H. Tanaka, S. Honda, H. Shimeno, N. Arima and S. Soeda: High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. *Int J Cancer*, 131(9), 2044-55 (2012)
DOI: 10.1002/ijc.27481
265. X. F. Qi, Y. J. Li, Z. Y. Chen, S. K. Kim, K. J. Lee and D. Q. Cai: Involvement of the FoxO3a pathway in the ischemia/reperfusion injury of cardiac microvascular endothelial cells. *Exp Mol Pathol*, 95(2), 242-7 (2013)
DOI: 10.1016/j.yexmp.2013.08.003
266. Y. Yang, Y. Su, D. Wang, Y. Chen, T. Wu, G. Li, X. Sun and L. Cui: Tanshinol attenuates the deleterious effects of oxidative stress on osteoblastic differentiation via Wnt/FoxO3a signaling. *Oxid Med Cell Longev*, 2013, 351895 (2013)
DOI: 10.1155/2013/351895
267. K. Lee, Y. Hu, L. Ding, Y. Chen, Y. Takahashi, R. Mott and J. X. Ma: Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. *Diabetes*, 61(11), 2948-57 (2012)
DOI: 10.2337/db11-0300
268. K. Maiese: WISP1: Clinical Insights for a Proliferative and Restorative Member of the CCN Family. *Curr Neurovasc Res*, 11(4), 378-389 (2014)
DOI: 10.2174/1567202611666140912115107
269. X. H. Wang, X. Sun, X. W. Meng, Z. W. Lv, Y. J. Du, Y. Zhu, J. Chen, D. X. Kong and S. Z. Jin: beta-catenin siRNA regulation of apoptosis- and angiogenesis-related gene expression in hepatocellular carcinoma cells: potential uses for gene therapy. *Oncol Rep*, 24(4), 1093-9 (2010)
270. J. Du, J. D. Klein, F. Hassounah, J. Zhang, C. Zhang and X. H. Wang: Aging increases CCN1 expression leading to muscle senescence. *Am J Physiol Cell Physiol*, 306(1), C28-36 (2014)
DOI: 10.1152/ajpcell.00066.2013
271. Y. Fu, H. Chang, X. Peng, Q. Bai, L. Yi, Y. Zhou, J. Zhu and M. Mi: Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/beta-catenin signaling pathway. *PLoS One*, 9(7), e102535 (2014)
DOI: 10.1371/journal.pone.0102535
272. N. Shah, Y. Morsi and R. Manasseh: From mechanical stimulation to biological pathways in the regulation of stem cell fate. *Cell Biochem Funct*, 32(4), 309-325 (2014)
DOI: 10.1002/cbf.3027
273. T. J. Sun, R. Tao, Y. Q. Han, G. Xu, J. Liu and Y. F. Han: Therapeutic potential of umbilical cord mesenchymal stem cells with Wnt/beta-catenin signaling pathway pre-activated for the treatment of diabetic wounds. *Eur Rev Med Pharmacol Sci*, 18(17), 2460-4 (2014)
274. A. Maeda, M. Ono, K. Holmbeck, L. Li, T. M. Kilts, V. Kram, M. L. Noonan, Y. Yoshioka, E. McNerny, M. Tantillo, D. Kohn, K. M. Lyons, P. G. Robey and M. F. Young: WNT1 induced secreted protein-1 (WISP1): A novel regulator of bone turnover and Wnt signaling. *J Biol Chem* (2015)
DOI: 10.1074/jbc.M114.628818
275. F. L'Episcopo, C. Tirolo, S. Caniglia, N. Testa,

- M. C. Morale, M. F. Serapide, S. Pluchino and B. Marchetti: Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. *J Mol Cell Biol*, 6(1), 13-26 (2014)
DOI: 10.1093/jmcb/mjt053
276. B. Marchetti and S. Pluchino: Wnt your brain be inflamed? Yes, it Wnt! *Trends Mol Med*, 19(3), 144-56 (2013)
DOI: 10.1016/j.molmed.2012.12.001
277. D. Ortiz-Masia, J. Cosin-Roger, S. Calatayud, C. Hernandez, R. Alos, J. Hinojosa, N. Apostolova, A. Alvarez and M. D. Barrachina: Hypoxic macrophages impair autophagy in epithelial cells through Wnt1: relevance in IBD. *Mucosal Immunol*, 7(4), 929-38 (2014)
278. D. J. Klinken, 2nd: Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. *PLoS Comput Biol*, 10(1), e1003409 (2014)
DOI: 10.1371/journal.pcbi.1003409
279. K. Knoblich, H. X. Wang, C. Sharma, A. L. Fletcher, S. J. Turley and M. E. Hemler: Tetraspanin TSPAN12 regulates tumor growth and metastasis and inhibits beta-catenin degradation. *Cell Mol Life Sci*, 71(7), 1305-14 (2014)
DOI: 10.1007/s00018-013-1444-8
280. K. Maiese, F. Li, Z. Z. Chong and Y. C. Shang: The Wnt signaling pathway: Aging gracefully as a protectionist? *Pharmacol Ther*, 118(1), 58-81 (2008)
DOI: 10.1016/j.pharmthera.2008.01.004
281. H. Y. Park, K. Toume, M. A. Arai, S. K. Sadhu, F. Ahmed and M. Ishibashi: Calotropin: a cardenolide from *calotropis gigantea* that inhibits Wnt signaling by increasing casein kinase 1 α in colon cancer cells. *Chembiochem*, 15(6), 872-8 (2014)
DOI: 10.1002/cbic.201300786
282. S. Bayod, P. Felice, P. Andres, P. Rosa, A. Camins, M. Pallas and A. M. Canudas: Downregulation of canonical Wnt signaling in hippocampus of SAMP8 mice. *Neurobiol Aging* (2014)
283. S. Bayod, I. Menella, S. Sanchez-Roige, J. F. Lanza, R. M. Escorihuela, A. Camins, M. Pallas and A. M. Canudas: Wnt pathway regulation by long-term moderate exercise in rat hippocampus. *Brain Res*, 1543, 38-48 (2014)
DOI: 10.1016/j.brainres.2013.10.048
284. D. C. Berwick and K. Harvey: The regulation and deregulation of Wnt signaling by PARK genes in health and disease. *J Mol Cell Biol*, 6(1), 3-12 (2014)
DOI: 10.1093/jmcb/mjt037
285. C. Gonzalez-Fernandez, C. M. Fernandez-Martos, S. Shields, E. Arenas and F. J. Rodriguez: Wnts are expressed in the spinal cord of adult mice and are differentially induced after injury. *J Neurotrauma* (2013)
286. D. Xu, W. Zhao, G. Pan, M. Qian, X. Zhu, W. Liu, G. Cai and Z. Cui: Expression of Nemo-like kinase after spinal cord injury in rats. *J Mol Neurosci*, 52(3), 410-8 (2014)
DOI: 10.1007/s12031-013-0191-5
287. N. Tabatadze, C. Tomas, R. McGonigal, B. Lin, A. Schook and A. Routtenberg: Wnt transmembrane signaling and long-term spatial memory. *Hippocampus*, 22(6), 1228-41 (2012)
DOI: 10.1002/hipo.20991
288. W. Loilome, P. Bungkanjana, A. Techasen, N. Namwat, P. Yongvanit, A. Puapairoj, N. Khuntikeo and G. J. Riggins: Activated macrophages promote Wnt/beta-catenin signaling in cholangiocarcinoma cells. *Tumour Biol* (2014)
DOI: 10.1007/s13277-014-1698-2
289. V. Murahovschi, O. Pivovarova, I. Ilkavets, R. M. Dmitrieva, S. Docke, F. Keyhani-Nejad, O. Gogebakan, M. Osterhoff, M. Kemper, S. Hornemann, M. Markova, N. Kloting, M. Stockmann, M. O. Weickert, V. Lamounier-Zepter, P. Neuhaus, A. Konradi, S. Dooley, C. von Loeffelholz, M. Bluher, A. F. Pfeiffer and N. Rudovich: WISP1 is a novel adipokine linked to inflammation in obesity. *Diabetes* (2014)
290. S. Wang, Z. Sun, X. Zhang, Z. Li, M. Wu, W. Zhao, H. Wang, T. Chen, H. Yan and J. Zhu: Wnt1 Positively Regulates CD36 Expression via TCF4 and PPAR- γ in Macrophages. *Cell Physiol Biochem*, 35(4), 1289-1302 (2015)
DOI: 10.1159/000373951
291. F. L'Episcopo, C. Tirolo, N. Testa, S. Caniglia, M. C. Morale, M. Deleidi, M. F. Serapide, S. Pluchino and B. Marchetti: Plasticity of Subventricular

- Zone Neuroprogenitors in MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) Mouse Model of Parkinson's Disease Involves Cross Talk between Inflammatory and Wnt/beta-Catenin Signaling Pathways: Functional Consequences for Neuroprotection and Repair. *J Neurosci*, 32(6), 2062-2085 (2012)
DOI: 10.1523/JNEUROSCI.5259-11.2012
292. L. Wei, L. Ding, M. S. Mo, M. Lei, L. Zhang, K. Chen and P. Xu: Wnt3a protects SH-SY5Y cells against 6-hydroxydopamine toxicity by restoration of mitochondria function. *Transl Neurodegener*, 4, 11 (2015)
DOI: 10.1186/s40035-015-0033-1
 293. F. Pilar-Cuellar, R. Vidal, A. Diaz, E. Castro, S. dos Anjos, J. Pascual-Brazo, R. Linge, V. Vargas, H. Blanco, B. Martinez-Villayandre, A. Pazos and E. M. Valdizan: Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. *Neural Plast*, 2013, 537265 (2013)
DOI: 10.1155/2013/537265
 294. Z. Z. Chong, Y. C. Shang, J. Hou and K. Maiese: Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. *Oxid Med Cell Longev*, 3(2), 153-65 (2010)
DOI: 10.4161/oxim.3.2.11758
 295. X. S. Xing, F. Liu and Z. Y. He: Akt regulates beta-catenin in a rat model of focal cerebral ischemia-reperfusion injury. *Mol Med Rep* (2014)
DOI: 10.3892/mmr.2014.3000
 296. Y. Xing, X. Zhang, K. Zhao, L. Cui, L. Wang, L. Dong, Y. Li, Z. Liu, C. Wang, X. Zhang, C. Zhu, H. Qiao, Y. Ji and X. Cao: Beneficial effects of sulindac in focal cerebral ischemia: a positive role in Wnt/beta-catenin pathway. *Brain Res*, 1482, 71-80 (2012)
DOI: 10.1016/j.brainres.2012.08.057
 297. E. M. Kawamoto, M. Gleichmann, L. M. Yshii, S. Lima Lde, M. P. Mattson and C. Scavone: Effect of activation of canonical Wnt signaling by the Wnt-3a protein on the susceptibility of PC12 cells to oxidative and apoptotic insults. *Braz J Med Biol Res*, 45(1), 58-67 (2012)
DOI: 10.1590/S0100-879X2011007500157
 298. N. Pecina-Slaus: Wnt signal transduction pathway and apoptosis: a review. *Cancer Cell Int*, 10, 22 (2010)
DOI: 10.1186/1475-2867-10-22
 299. Y. Peng, B. H. Jiang, P. H. Yang, Z. Cao, X. Shi, M. C. Lin, M. L. He and H. F. Kung: Phosphatidylinositol 3-kinase signaling is involved in neurogenesis during *Xenopus* embryonic development. *J Biol Chem*, 279(27), 28509-14 (2004)
DOI: 10.1074/jbc.M402294200
 300. S. Wang, Z. Z. Chong, Y. C. Shang and K. Maiese: WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy. *Curr Neurovasc Res*, 9(2), 89-99 (2012)
DOI: 10.2174/156720212800410858
 301. B. Berschneider, D. C. Ellwanger, H. A. Baarsma, C. Thiel, C. Shimbori, E. S. White, M. Kolb, P. Neth and M. Konigshoff: miR-92a regulates TGF-beta1-induced WISP1 expression in pulmonary fibrosis. *Int J Biochem Cell Biol*, 53, 432-41 (2014)
DOI: 10.1016/j.biocel.2014.06.011
 302. S. Schneider, P. Kloimstein, J. Pammer, W. Brannath, M. Grasl and B. M. Erovic: New diagnostic markers in salivary gland tumors. *Eur Arch Otorhinolaryngol*, 271(7), 1999-2007 (2014)
DOI: 10.1007/s00405-013-2740-5
 303. M. H. van den Bosch, A. B. Blom, P. L. van Lent, H. M. van Beuningen, E. N. Blaney Davidson, P. M. van der Kraan and W. B. van den Berg: Canonical Wnt signaling skews TGF-beta signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8. *Cell Signal*, 26(5), 951-8 (2014)
DOI: 10.1016/j.cellsig.2014.01.021
 304. H. Liu, J. Yin, H. Wang, G. Jiang, M. Deng, G. Zhang, X. Bu, S. Cai, J. Du and Z. He: FOXO3a modulates WNT/beta-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. *Cell Signal*, 27(3), 510-8 (2015)
DOI: 10.1016/j.cellsig.2015.01.001
 305. M. Almeida, L. Han, M. Martin-Millan, C. A. O'Brien and S. C. Manolagas: Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. *J Biol Chem*, 282(37), 27298-305 (2007)
DOI: 10.1074/jbc.M702811200

306. Y. Kashii, M. Uchida, K. Kirito, M. Tanaka, K. Nishijima, M. Toshima, T. Ando, K. Koizumi, T. Endoh, K. Sawada, M. Momoi, Y. Miura, K. Ozawa and N. Komatsu: A member of Forkhead family transcription factor, FKHL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. *Blood*, 96(3), 941-9. (2000)
307. W. J. Bakker, T. B. van Dijk, M. Parren-van Amelsvoort, A. Kolbus, K. Yamamoto, P. Steinlein, R. G. Verhaak, T. W. Mak, H. Beug, B. Lowenberg and M. von Lindern: Differential regulation of Foxo3a target genes in erythropoiesis. *Mol Cell Biol*, 27(10), 3839-3854 (2007)
DOI: 10.1128/MCB.01662-06
308. D. Bouscary, F. Pene, Y. E. Claessens, O. Muller, S. Chretien, M. Fontenay-Roupie, S. Gisselbrecht, P. Mayeux and C. Lacombe: Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. *Blood*, 101(9), 3436-43 (2003)
DOI: 10.1182/blood-2002-07-2332
309. D. L. Mahmud, G. A. M, D. K. Deb, L. C. Platanias, S. Uddin and A. Wickrema: Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. *Oncogene*, 21(10), 1556-62 (2002)
DOI: 10.1038/sj.onc.1205230
310. Z. Z. Chong, Y. C. Shang, S. Wang and K. Maiese: PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection. *PLoS ONE*, 7(9), e45456 (2012)
DOI: 10.1371/journal.pone.0045456
311. W. J. Bakker, M. Blazquez-Domingo, A. Kolbus, J. Besooyen, P. Steinlein, H. Beug, P. J. Coffey, B. Lowenberg, M. von Lindern and T. B. van Dijk: FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. *J Cell Biol*, 164(2), 175-84 (2004)
DOI: 10.1083/jcb.200307056
312. K. Maiese, J. Hou, Z. Z. Chong and Y. C. Shang: Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. *ScientificWorldJournal*, 9, 1072-104 (2009)
DOI: 10.1100/tsw.2009.121
313. H. Zhao, R. Wang, X. Wu, J. Liang, Z. Qi, X. Liu, L. Min, X. Ji and Y. Luo: Erythropoietin delivered via intra-arterial infusion reduces endoplasmic reticulum stress in brain microvessels of rats following cerebral ischemia and reperfusion. *J Neuroimmune Pharmacol*, 10(1), 153-61 (2015)
DOI: 10.1007/s11481-014-9571-z
314. L. Wang, R. Teng, L. Di, H. Rogers, H. Wu, J. B. Kopp and C. T. Noguchi: PPARalpha and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. *Diabetes*, 62(12), 4122-31 (2013)
DOI: 10.2337/db13-0518
315. L. Wang, Y. Jia, H. Rogers, Y. P. Wu, S. Huang and C. T. Noguchi: GATA-binding protein 4 (GATA-4) and T-cell acute leukemia 1 (TAL1) regulate myogenic differentiation and erythropoietin response via cross-talk with Sirtuin1 (Sirt1). *J Biol Chem*, 287(36), 30157-69 (2012)
DOI: 10.1074/jbc.M112.376640
316. Z. Z. Chong, Y. C. Shang and K. Maiese: Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. *Curr Neurovasc Res*, 4(3), 194-204 (2007)
DOI: 10.2174/156720207781387150
317. L. Danielyan, R. Schafer, A. Schulz, T. Ladewig, A. Lourhmati, M. Buadze, A. L. Schmitt, S. Verleysdonk, D. Kabisch, K. Koepfen, G. Siegel, B. Proksch, T. Kluba, A. Eckert, C. Kohle, T. Schoneberg, H. Northoff, M. Schwab and C. H. Gleiter: Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. *Cell Death Differ*, 16(12), 1599-614 (2009)
DOI: 10.1038/cdd.2009.95
318. X. Chen, C. C. Wang, S. M. Song, S. Y. Wei, J. S. Li, S. L. Zhao and B. Li: The administration of erythropoietin attenuates kidney injury induced by ischemia/reperfusion with increased activation of Wnt/beta-catenin signaling. *J Formos Med Assoc*, 114(5), 430-7 (2015)
DOI: 10.1016/j.jfma.2015.01.007
319. K. Maiese: MicroRNAs and Stem Cells to the Rescue. *Curr Neurovasc Res* (2015)
DOI: 10.2174/156720261203150701142445

320. S. C. Johnson, M. Sangesland, M. Kaeberlein and P. S. Rabinovitch: Modulating mTOR in aging and health. *Interdiscip Top Gerontol*, 40, 107-27 (2015)
DOI: 10.1159/000364974
321. J. Neasta, S. Barak, S. B. Hamida and D. Ron: mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse. *J Neurochem*, 130(2), 172-84 (2014)
DOI: 10.1111/jnc.12725
322. C. Wang, J. T. Yu, D. Miao, Z. C. Wu, M. S. Tan and L. Tan: Targeting the mTOR Signaling Network for Alzheimer's Disease Therapy. *Mol Neurobiol*, 49(1), 120-35 (2014)
DOI: 10.1007/s12035-013-8505-8
323. Z. Z. Chong, Y. C. Shang, L. Zhang, S. Wang and K. Maiese: Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. *Oxid Med Cell Longev*, 3(6), 374-91 (2010)
DOI: 10.4161/oxim.3.6.14787
324. Z. Z. Chong and K. Maiese: Mammalian Target of Rapamycin Signaling in Diabetic Cardiovascular Disease. *Cardiovasc Diabetol*, 11(1), 45 (2012)
DOI: 10.1186/1475-2840-11-45
325. A. K. Saha, X. J. Xu, E. Lawson, R. Deoliveira, A. E. Brandon, E. W. Kraegen and N. B. Ruderman: Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. *Diabetes*, 59(10), 2426-34 (2010)
DOI: 10.2337/db09-1870
326. P. B. Martinez de Morentin, N. Martinez-Sanchez, J. Roa, J. Ferno, R. Nogueiras, M. Tena-Sempere, C. Dieguez and M. Lopez: Hypothalamic mTOR: the rookie energy sensor. *Curr Mol Med*, 14(1), 3-21 (2014)
DOI: 10.2174/1566524013666131118103706
327. Z. Cai, B. Li, K. Li and B. Zhao: Down-regulation of amyloid-beta through AMPK activation by inhibitors of GSK-3beta in SH-SY5Y and SH-SY5Y-AbetaPP695 cells. *J Alzheimers Dis*, 29(1), 89-98 (2012)
328. H. Zhao, Z. C. Wang, K. F. Wang and X. Y. Chen: A-beta peptide secretion is reduced by Radix Polygalae-induced autophagy via activation of the AMPK/mTOR pathway. *Mol Med Rep* (2015)
329. L. L. Du, D. M. Chai, L. N. Zhao, X. H. Li, F. C. Zhang, H. B. Zhang, L. B. Liu, K. Wu, R. Liu, J. Z. Wang and X. W. Zhou: AMPK Activation Ameliorates Alzheimer's Disease-Like Pathology and Spatial Memory Impairment in a Streptozotocin-Induced Alzheimer's Disease Model in Rats. *J Alzheimers Dis* (2014)
330. T. Jiang, J. T. Yu, X. C. Zhu, H. F. Wang, M. S. Tan, L. Cao, Q. Q. Zhang, L. Gao, J. Q. Shi, Y. D. Zhang and L. Tan: Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. *Br J Pharmacol*, 171(13), 3146-57 (2014)
DOI: 10.1111/bph.12655
331. N. Moroz, J. J. Carmona, E. Anderson, A. C. Hart, D. A. Sinclair and T. K. Blackwell: Dietary restriction involves NAD⁺-dependent mechanisms and a shift toward oxidative metabolism. *Aging Cell*, 13(6), 1075-1085 (2014)
DOI: 10.1111/accel.12273
332. E. Russo, F. Andreozzi, R. Iuliano, V. Dattilo, T. Procopio, G. Fiume, S. Mimmi, N. Perrotti, R. Citraro, G. Sesti, A. Constanti and G. De Sarro: Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release. *Brain Behav Immun*, 42, 157-168 (2014)
DOI: 10.1016/j.bbi.2014.06.016
333. F. Y. Guan, J. Gu, W. Li, M. Zhang, Y. Ji, J. Li, L. Chen and G. M. Hatch: Compound K protects pancreatic islet cells against apoptosis through inhibition of the AMPK/JNK pathway in type 2 diabetic mice and in MIN6 beta-cells. *Life Sci*, 107(1-2), 42-9 (2014)
DOI: 10.1016/j.lfs.2014.04.034
334. L. Chen, B. Xu, L. Liu, Y. Luo, J. Yin, H. Zhou, W. Chen, T. Shen, X. Han and S. Huang: Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. *Lab Invest*, 90(5), 762-73 (2010)
DOI: 10.1038/labinvest.2010.36
335. A. Salminen, K. Kaarniranta, A. Haapasalo, H. Soininen and M. Hiltunen: AMP-activated protein kinase: a potential player in Alzheimer's

- disease. *J Neurochem*, 118(4), 460-74 (2011)
DOI: 10.1111/j.1471-4159.2011.07331.x
336. G. Marfia, L. Madaschi, F. Marra, M. Menarini, D. Bottai, A. Formenti, C. Bellardita, A. M. Di Giulio, S. Carelli and A. Gorio: Adult neural precursors isolated from post mortem brain yield mostly neurons: an erythropoietin-dependent process. *Neurobiol Dis*, 43(1), 86-98 (2011)
DOI: 10.1016/j.nbd.2011.02.004
 337. K. P. Sanghera, N. Mathalone, R. Baigi, E. Panov, D. Wang, X. Zhao, H. Hsu, H. Wang, V. Tropepe, M. Ward and S. R. Boyd: The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress. *Mol Cell Neurosci*, 47(2), 145-53 (2011)
DOI: 10.1016/j.mcn.2011.03.010
 338. M. G. Ryou, G. R. Choudhury, W. Li, A. Winters, F. Yuan, R. Liu and S. H. Yang: Methylene blue-induced neuronal protective mechanism against hypoxia-reoxygenation stress. *Neuroscience*, 301, 193-203 (2015)
DOI: 10.1016/j.neuroscience.2015.05.064
 339. L. Wang, L. Di and C. T. Noguchi: AMPK is involved in mediation of erythropoietin influence on metabolic activity and reactive oxygen species production in white adipocytes. *Int J Biochem Cell Biol*, 54, 1-9 (2014)
DOI: 10.1016/j.biocel.2014.06.008
 340. M. Andreucci, G. Fuiano, P. Presta, G. Lucisano, F. Leone, L. Fuiano, V. Bisesti, P. Esposito, D. Russo, B. Memoli, T. Faga and A. Michael: Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. *Cell Prolif*, 42(4), 554-61 (2009)
DOI: 10.1111/j.1365-2184.2009.00617.x
 341. X. Guo, Y. Chen, Q. Liu, J. Wu, L. Wang, X. Tang, W. Zhao and H. Zhang: Ac-cel, a novel antioxidant, protects against hydrogen peroxide-induced injury in PC12 cells via attenuation of mitochondrial dysfunction. *J Mol Neurosci*, 50(3), 453-61 (2013)
DOI: 10.1007/s12031-013-9955-1
 342. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Targeting disease through novel pathways of apoptosis and autophagy. *Expert Opin Ther Targets*, 16(12), 1203-14 (2012)
DOI: 10.1517/14728222.2012.719499
 343. B. Favaloro, N. Allocati, V. Graziano, C. Di Ilio and V. De Laurenzi: Role of Apoptosis in disease. *Aging (Albany NY)*, 4(5), 330-49 (2012)
 344. J. Folch, F. Junyent, E. Verdaguer, C. Auladell, J. G. Pizarro, C. Beas-Zarate, M. Pallas and A. Camins: Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death. *Neurotox Res*, 22(3), 195-207 (2012)
DOI: 10.1007/s12640-011-9277-4
 345. A. Q. Nguyen, B. H. Cherry, G. F. Scott, M. G. Ryou and R. T. Mallet: Erythropoietin: Powerful protection of ischemic and post-ischemic brain. *Exp Biol Med (Maywood)* (2014)
 346. S. Shao, Y. Yang, G. Yuan, M. Zhang and X. Yu: Signaling molecules involved in lipid-induced pancreatic Beta-cell dysfunction. *Dna Cell Biol*, 32(2), 41-9 (2013)
DOI: 10.1089/dna.2012.1874
 347. J. Q. Kang, Z. Z. Chong and K. Maiese: Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. *Mol Pharmacol*, 64(3), 557-69 (2003)
DOI: 10.1124/mol.64.3.557
 348. K. Schutters and C. Reutelingsperger: Phosphatidylserine targeting for diagnosis and treatment of human diseases. *Apoptosis*, 15(9), 1072-82 (2010)
DOI: 10.1007/s10495-010-0503-y
 349. G. Viola, R. Bortolozzi, E. Hamel, S. Moro, P. Brun, I. Castagliuolo, M. G. Ferlin and G. Basso: MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. *Biochem Pharmacol*, 83(1), 16-26 (2012)
DOI: 10.1016/j.bcp.2011.09.017
 350. S. R. Haldar, A. Chakrabarty, S. Chowdhury, A. Haldar, S. Sengupta and M. Bhattacharyya: Oxidative Stress-Related Genes in Type 2 Diabetes: Association Analysis and Their Clinical Impact. *Biochem Genet* (2015)
DOI: 10.1007/s10528-015-9675-z
 351. K. Maiese, Z. Z. Chong, S. Wang and Y. C. Shang: Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade. *Int J Mol*

- Sci, 13(11), 13830-66 (2013)
352. H. E. Palma, P. Wolkmer, M. Gallio, M. M. Correa, R. Schmatz, G. R. Thome, L. B. Pereira, V. S. Castro, A. B. Pereira, A. Bueno, L. S. de Oliveira, D. Rosolen, T. R. Mann, B. S. de Cecco, D. L. Graca, S. T. Lopes and C. M. Mazzanti: Oxidative stress parameters in blood, liver, and kidney of diabetic rats treated with curcumin and/or insulin. *Mol Cell Biochem*, 386(1-2), 199-210 (2014)
DOI: 10.1007/s11010-013-1858-5
 353. C. Bowes Rickman, S. Farsiu, C. A. Toth and M. Klingeborn: Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. *Invest Ophthalmol Vis Sci*, 54(14), ORSF68-80 (2013)
DOI: 10.1167/iops.13-12757
 354. J. A. Miret and S. Munne-Bosch: Plant amino acid-derived vitamins: biosynthesis and function. *Amino Acids*, 46(4), 809-24 (2014)
DOI: 10.1007/s00726-013-1653-3
 355. Y. J. Xu, P. S. Tappia, N. S. Neki and N. S. Dhalla: Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. *Heart Fail Rev*, 19(1), 113-21 (2014)
DOI: 10.1007/s00726-013-1653-3
 356. J. M. Yousef and A. M. Mohamed: Prophylactic role of B vitamins against bulk and zinc oxide nano-particles toxicity induced oxidative DNA damage and apoptosis in rat livers. *Pak J Pharm Sci*, 28(1), 175-84 (2015)
 357. K. Rjiba-Touati, I. Ayed-Boussema, Y. Guedri, A. Achour, H. Bacha and S. Abid-Essefi: Effect of recombinant human erythropoietin on mitomycin C-induced oxidative stress and genotoxicity in rat kidney and heart tissues. *Hum Exp Toxicol* (2015)
DOI: 10.1177/0960327115577521
 358. L. Moreira, J. M. Beirao, I. Beirao and P. P. Costa: Oligomeric TTR V30M aggregates compromise cell viability, erythropoietin gene expression and promoter activity in the human hepatoma cell line Hep3B. *Amyloid*, 1-7 (2015)
DOI: 10.3109/13506129.2015.1007497
 359. T. Yu, L. Li, T. Chen, Z. Liu, H. Liu and Z. Li: Erythropoietin attenuates advanced glycation endproducts-induced toxicity of schwann cells *in vitro*. *Neurochem Res*, 40(4), 698-712 (2015)
DOI: 10.1007/s11064-015-1516-2
 360. X. Zhang, S. Dong, Y. Qin and X. Bian: Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms. *Mol Med Rep*, 11(5), 3317-29 (2015)
DOI: 10.3892/mmr.2015.3155
 361. T. Ishii, T. Asai, T. Fukuta, D. Oyama, N. Yasuda, Y. Agato, K. Shimizu, T. Minamino and N. Oku: A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusion. *Int J Pharm*, 439(1-2), 269-74 (2012)
DOI: 10.1016/j.ijpharm.2012.09.026
 362. Z. Z. Chong, F. Li and K. Maiese: Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. *Curr Neurovasc Res*, 2(5), 387-99 (2005)
DOI: 10.2174/156720205774962683
 363. P. Esmaeili Tazangi, S. M. Moosavi, M. Shabani and M. Haghani: Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease. *Pharmacol Biochem Behav*, 130, 15-21 (2015)
DOI: 10.1016/j.pbb.2014.12.011
 364. S. T. Lee, K. Chu, J. E. Park, K. H. Jung, D. Jeon, J. Y. Lim, S. K. Lee, M. Kim and J. K. Roh: Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. *J Neurochem*, 120(1), 115-24 (2012)
DOI: 10.1111/j.1471-4159.2011.07534.x
 365. P. E. Sanchez, R. P. Fares, J. J. Risso, C. Bonnet, S. Bouvard, M. Le-Cavorsin, B. Georges, C. Moulin, A. Belmeguenai, J. Bodennec, A. Morales, J. M. Pequignot, E. E. Baulieu, R. A. Levine and L. Bezin: Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. *Proc Natl Acad Sci U S A*, 106(24), 9848-53 (2009)
DOI: 10.1073/pnas.0901840106
 366. J. Soliz, J. J. Thomsen, C. Soulage, C. Lundby and M. Gassmann: Sex-dependent regulation of hypoxic ventilation in mice and humans is mediated by erythropoietin. *Am J*

- Physiol Regul Integr Comp Physiol*, 296(6), R1837-46 (2009)
DOI: 10.1152/ajpregu.90967.2008
367. C. Caprara, C. Britschgi, M. Samardzija and C. Grimm: The erythropoietin receptor is not required for the development, function, and aging of rods and cells in the retinal periphery. *Mol Vis*, 20, 307-24 (2014)
 368. W. Shen, S. H. Chung, M. R. Irhimeh, S. Li, S. R. Lee and M. C. Gillies: Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats. *PLoS One*, 9(8), e104759 (2014)
DOI: 10.1371/journal.pone.0104759
 369. D. Choi, S. A. Schroer, S. Y. Lu, L. Wang, X. Wu, Y. Liu, Y. Zhang, H. Y. Gaisano, K. U. Wagner, H. Wu, R. Retnakaran and M. Woo: Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. *J Exp Med*, 207(13), 2831-42 (2010)
DOI: 10.1084/jem.20100665
 370. T. Yu, L. Li, Y. Bi, Z. Liu, H. Liu and Z. Li: Erythropoietin attenuates oxidative stress and apoptosis in Schwann cells isolated from streptozotocin-induced diabetic rats. *J Pharm Pharmacol* (2014)
DOI: 10.1111/jphp.12244
 371. Z. Z. Chong, J. Q. Kang and K. Maiese: Apaf-1, Bcl-xL, Cytochrome c, and Caspase-9 Form the Critical Elements for Cerebral Vascular Protection by Erythropoietin. *J Cereb Blood Flow Metab*, 23(3), 320-30 (2003)
DOI: 10.1097/00004647-200303000-00007
 372. K. R. Dimitrova and I. M. Leitman: Intramyocardial transplantation of endothelial progenitor cells and erythropoietin: a new scope for the treatment of cardiovascular disease. *J Surg Res*, 183(2), 550-2 (2013)
DOI: 10.1016/j.jss.2012.05.010
 373. E. Gammella, C. Leuenberger, M. Gassmann and L. Ostergaard: Evidence of synergistic/additive effects of sildenafil and erythropoietin in enhancing survival and migration of hypoxic endothelial cells. *Am J Physiol Lung Cell Mol Physiol*, 304(4), L230-9 (2013)
DOI: 10.1152/ajplung.00112.2012
 374. S. Hamed, D. Egozi, D. Kruchevsky, L. Teot, A. Gilhar and Y. Ullmann: Erythropoietin improves the survival of fat tissue after its transplantation in nude mice. *PLoS ONE*, 5(11), e13986 (2010)
DOI: 10.1371/journal.pone.0013986
 375. S. Hamed, Y. Ullmann, D. Egozi, E. Daod, E. Hellou, M. Ashkar, A. Gilhar and L. Teot: Fibronectin potentiates topical erythropoietin-induced wound repair in diabetic mice. *J Invest Dermatol*, 131(6), 1365-74 (2011)
DOI: 10.1038/jid.2011.15
 376. M. Kamianowska, M. Szczepanski and E. Skrzydlewska: Effects of erythropoietin on ICAM-1 and PECAM-1 expressions on human umbilical vein endothelial cells subjected to oxidative stress. *Cell Biochem Funct*, 29(6), 437-41 (2011)
DOI: 10.1002/cbf.1768
 377. W. S. Bond and T. S. Rex: Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia. *Front Immunol*, 5, 523 (2014)
DOI: 10.3389/fimmu.2014.00523
 378. M. M. Loeliger, A. Mackintosh, R. De Matteo, R. Harding and S. M. Rees: Erythropoietin protects the developing retina in an ovine model of endotoxin-induced retinal injury. *Invest Ophthalmol Vis Sci*, 52(5), 2656-61 (2011)
DOI: 10.1167/iovs.10-6455
 379. N. Miljus, S. Heibeck, M. Jarrar, M. Micke, D. Ostrowski, H. Ehrenreich and R. Heinrich: Erythropoietin-mediated protection of insect brain neurons involves JAK and STAT but not PI3K transduction pathways. *Neuroscience*, 258, 218-27 (2014)
DOI: 10.1016/j.neuroscience.2013.11.020
 380. S. Pankratova, B. Gu, D. Kiryushko, I. Korshunova, L. B. Kohler, M. Rathje, E. Bock and V. Berezin: A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival. *J Neurochem*, 121(6), 915-23 (2012)
DOI: 10.1111/j.1471-4159.2012.07751.x
 381. S. D. Wenker, M. E. Chamorro, D. C. Vittori and A. B. Nesse: Protective action of erythropoietin on neuronal damage induced by activated microglia. *FEBS J*, 280(7), 1630-42 (2013)
DOI: 10.1111/febs.12172
 382. T. F. Zhou and J. G. Yu: Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3

- signaling in experimental endotoxemia. *J Surg Res*, 183(1), 304-12 (2013)
DOI: 10.1016/j.jss.2012.11.035
383. A. Lourhmati, G. H. Buniatian, C. Paul, S. Verleysdonk, R. Buecheler, M. Buadze, B. Proksch, M. Schwab, C. H. Gleiter and L. Danielyan: Age-dependent astroglial vulnerability to hypoxia and glutamate: the role for erythropoietin. *PLoS One*, 8(10), e77182 (2013)
DOI: 10.1371/journal.pone.0077182
 384. R. Schafer, L. Mueller, R. Buecheler, B. Proksch, M. Schwab, C. H. Gleiter and L. Danielyan: Interplay between Endothelin and Erythropoietin in Astroglia: The Role in Protection against Hypoxia. *Int J Mol Sci*, 15(2), 2858-75 (2014)
DOI: 10.3390/ijms15022858
 385. M. Yamada, C. Burke, P. Colditz, D. W. Johnson and G. C. Gobe: Erythropoietin protects against apoptosis and increases expression of non-neuronal cell markers in the hypoxia-injured developing brain. *J Pathol*, 224(1), 101-9 (2011)
DOI: 10.1002/path.2862
 386. N. Kaneko, E. Kako and K. Sawamoto: Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives. *Front Cell Neurosci*, 7, 235 (2013)
DOI: 10.3389/fncel.2013.00235
 387. Y. Xu, Y. Tian, H. J. Wei, J. Chen, J. F. Dong, A. Zacharek and J. N. Zhang: Erythropoietin increases circulating endothelial progenitor cells and reduces the formation and progression of cerebral aneurysm in rats. *Neuroscience*, 181, 292-9 (2011)
DOI: 10.1016/j.neuroscience.2011.02.051
 388. M. H. Hussein, G. A. Daoud, H. Kakita, S. Kato, T. Goto, M. Kamei, K. Goto, M. Nobata, Y. Ozaki, T. Ito, S. Fukuda, I. Kato, S. Suzuki, H. Sobajima, F. Hara, T. Hashimoto and H. Togari: High cerebrospinal fluid antioxidants and interleukin 8 are protective of hypoxic brain damage in newborns. *Free Radic Res*, 44(4), 422-9 (2010)
DOI: 10.3109/10715760903548245
 389. K. H. Park, N. Y. Choi, S. H. Koh, H. H. Park, Y. S. Kim, M. J. Kim, S. J. Lee, H. J. Yu, K. Y. Lee, Y. J. Lee and H. T. Kim: L-DOPA neurotoxicity is prevented by neuroprotective effects of erythropoietin. *Neurotoxicology*, 32(6), 879-87 (2011)
DOI: 10.1016/j.neuro.2011.05.009
 390. Z. Y. Wang, L. J. Shen, L. Tu, D. N. Hu, G. Y. Liu, Z. L. Zhou, Y. Lin, L. H. Chen and J. Qu: Erythropoietin protects retinal pigment epithelial cells from oxidative damage. *Free Radic Biol Med*, 46(8), 1032-41 (2009)
DOI: 10.1016/j.freeradbiomed.2008.11.027
 391. J. Dang, R. Jia, Y. Tu, S. Xiao and G. Ding: Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. *Biomed Pharmacother*, 64(10), 681-5 (2010)
DOI: 10.1016/j.biopha.2010.06.011
 392. A. Francois, F. Terro, N. Quellard, B. Fernandez, D. Chassaing, T. Janet, A. Rioux-Bilan, M. Paccalin and G. Page: Impairment of autophagy in the central nervous system during lipopolysaccharide-induced inflammatory stress in mice. *Mol Brain*, 7(1), 56 (2014)
DOI: 10.1186/s13041-014-0056-z
 393. H. Vakifahmetoglu-Norberg, H. G. Xia and J. Yuan: Pharmacologic agents targeting autophagy. *J Clin Invest*, 125(1), 5-13 (2015)
DOI: 10.1172/JCI73937
 394. C. He, H. Zhu, H. Li, M. H. Zou and Z. Xie: Dissociation of Bcl-2-Bec1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes. *Diabetes*, 62(4), 1270-81 (2013)
DOI: 10.2337/db12-0533
 395. K. A. Kim, Y. J. Shin, M. Akram, E. S. Kim, K. W. Choi, H. Suh, C. H. Lee and O. N. Bae: High glucose condition induces autophagy in endothelial progenitor cells contributing to angiogenic impairment. *Biol Pharm Bull*, 37(7), 1248-52 (2014)
DOI: 10.1248/bpb.b14-00172
 396. Y. M. Lim, H. Lim, K. Y. Hur, W. Quan, H. Y. Lee, H. Cheon, D. Ryu, S. H. Koo, H. L. Kim, J. Kim, M. Komatsu and M. S. Lee: Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes. *Nat Commun*, 5, 4934 (2014)
DOI: 10.1038/ncomms5934
 397. A. Bargiela, E. Cerro-Herreros, J. M. Fernandez-Costa, J. J. Vilchez, B. Llamusi

- and R. Artero: Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 *Drosophila* model. *Dis Model Mech*, 8(7), 679-90 (2015)
DOI: 10.1242/dmm.018127
398. W. Dong, R. Wang, L. N. Ma, B. L. Xu, J. S. Zhang, Z. W. Zhao, Y. L. Wang and X. Zhang: Influence of age-related learning and memory capacity of mice: different effects of a high and low caloric diet. *Aging Clin Exp Res* (2015)
DOI: 10.1007/s40520-015-0398-0
 399. I. Bendix, C. Schulze, C. Haefen, A. Gellhaus, S. Endesfelder, R. Heumann, U. Felderhoff-Mueser and M. Siffringer: Erythropoietin modulates autophagy signaling in the developing rat brain in an in vivo model of oxygen-toxicity. *Int J Mol Sci*, 13(10), 12939-51 (2012)
DOI: 10.3390/ijms131012939
 400. W. Jang, H. J. Kim, H. Li, K. D. Jo, M. K. Lee and H. O. Yang: The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy. *Mol Neurobiol* (2015)
DOI: 10.1007/s12035-015-9316-x
 401. R. Bierer, M. C. Peceny, C. H. Hartenberger and R. K. Ohls: Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. *Pediatrics*, 118(3), e635-40 (2006)
DOI: 10.1542/peds.2005-3186
 402. R. H. Leuchter, L. Gui, A. Poncet, C. Hagmann, G. A. Lodygensky, E. Martin, B. Koller, A. Darque, H. U. Bucher and P. S. Huppi: Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. *JAMA*, 312(8), 817-24 (2014)
DOI: 10.1001/jama.2014.9645
 403. C. S. Robertson, H. J. Hannay, J. M. Yamal, S. Gopinath, J. C. Goodman, B. C. Tilley, A. Baldwin, L. Rivera Lara, H. Saucedo-Crespo, O. Ahmed, S. Sadasivan, L. Ponce, J. Cruz-Navarro, H. Shahin, I. P. Aisiku, P. Doshi, A. Valadka, L. Neipert, J. M. Waguspack, M. L. Rubin, J. S. Benoit and P. Swank: Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. *JAMA*, 312(1), 36-47 (2014)
DOI: 10.1001/jama.2014.6490
 404. S. C. Cramer and M. D. Hill: Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial). *Int J Stroke*, 9(3), 321-7 (2014)
DOI: 10.1111/ijss.12260
 405. R. Castelli, G. L. Delilieri, R. Colombo, G. Moreo, P. Gallipoli and G. Pantaleo: Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. *Ann Hematol*, 93(9), 1523-9 (2014)
DOI: 10.1007/s00277-014-2070-8
 406. W. Jang, J. Park, K. J. Shin, J. S. Kim, J. S. Kim, J. Youn, J. W. Cho, E. Oh, J. Y. Ahn, K. W. Oh and H. T. Kim: Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. *J Neurol Sci*, 337(1-2), 47-54 (2014)
DOI: 10.1016/j.jns.2013.11.015
 407. S. S. Najjar, S. V. Rao, C. Melloni, S. V. Raman, T. J. Povsic, L. Melton, G. W. Barsness, K. Prather, J. F. Heitner, R. Kilaru, L. Gruberg, V. Hasselblad, A. B. Greenbaum, M. Patel, R. J. Kim, M. Talan, L. Ferrucci, D. L. Longo, E. G. Lakatta and R. A. Harrington: Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. *Jama*, 305(18), 1863-72 (2011)
DOI: 10.1001/jama.2011.592
 408. N. Taniguchi, T. Nakamura, T. Sawada, K. Matsubara, K. Furukawa, M. Hadase, Y. Nakahara and H. Matsubara: Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. *Circ J*, 74(11), 2365-71 (2010)
DOI: 10.1253/circj.CJ-10-0267
 409. Y. Wen, J. Xu, X. Ma and Q. Gao: High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. *Am J Cardiovasc Drugs*, 13(6), 435-42 (2013)
DOI: 10.1007/s40256-013-0042-3
 410. M. W. Bergmann, S. Haufe, F. von Knobelsdorff-Brenkenhoff, H. Mehling, R. Wassmuth, I. Munch, A. Busjahn, J. Schulz-Menger, J. Jordan, F. C. Luft and R. Dietz: A pilot study of chronic, low-dose epoetin- β following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with

- symptomatic ischaemic heart failure. *Eur J Heart Fail*, 13(5), 560-8 (2011)
DOI: 10.1093/eurjhf/hfr002
411. B. D. Hedley, A. L. Allan and A. Xenocostas: The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. *Clin Cancer Res*, 17(20), 6373-80 (2011)
DOI: 10.1158/1078-0432.CCR-10-2577
 412. K. Maiese, F. Li and Z. Z. Chong: Erythropoietin and cancer. *JAMA*, 293(15), 1858-1859 (2005)
 413. C. Zhang, Z. Li, Q. Cao, C. Qin, H. Cai, H. Zhou, J. Qian, L. Tao, X. Ju and C. Yin: Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population. *J Biomed Res*, 28(6), 456-461 (2014)
 414. M. Li, Q. Li, Y. H. Zhang, Z. Y. Tian, H. X. Ma, J. Zhao, S. Q. Xie and C. J. Wang: Antitumor effects and preliminary systemic toxicity of ANISpm *in vivo* and *in vitro*. *Anticancer Drugs*, 24(1), 32-42 (2013)
DOI: 10.1097/CAD.0b013e328359affd
 415. K. Maiese: Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR. *Indian J Med Res*, 137(2), 243-6 (2013)
 416. R. Malla, C. R. Ashby, Jr., N. K. Narayanan, B. Narayanan, J. S. Faridi and A. K. Tiwari: Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer. *Biochem Biophys Res Commun* (2015)
DOI: 10.1016/j.bbrc.2015.05.041
 417. F. Barbieri, M. Albertelli, F. Grillo, A. Mohamed, A. Saveanu, A. Barlier, D. Ferone and T. Florio: Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. *Drug Discov Today*, 19(4), 458-468 (2014)
DOI: 10.1016/j.drudis.2013.10.015
 418. V. N. Kolev, Q. G. Wright, C. M. Vidal, J. E. Ring, I. M. Shapiro, J. Ricono, D. T. Weaver, M. V. Padval, J. A. Pachter and Q. Xu: PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. *Cancer Res*, 75(2), 446-55 (2015)
DOI: 10.1158/0008-5472.CAN-14-1223
 419. K. Maiese: Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme. *J Transl Sci*, 1(1), 2 (2015)
 420. Z. H. Yang, R. Zheng, Y. Gao, Q. Zhang and H. Zhang: Abnormal gene expression and gene fusion in lung adenocarcinoma with high-throughput RNA sequencing. *Cancer Gene Ther*, 21(2), 74-82 (2014)
DOI: 10.1038/cgt.2013.86
 421. B. Zhou, J. S. Damrauer, S. T. Bailey, T. Hadzic, Y. Jeong, K. Clark, C. Fan, L. Murphy, C. Y. Lee, M. A. Troester, C. R. Miller, J. Jin, D. Darr, C. M. Perou, R. L. Levine, M. Diehn and W. Y. Kim: Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. *J Clin Invest*, 124(2), 553-63 (2014)
DOI: 10.1172/JCI69804
 422. H. Skali, H. H. Parving, P. S. Parfrey, E. A. Burdmann, E. F. Lewis, P. Ivanovich, S. R. Keithi-Reddy, J. B. McGill, J. J. McMurray, A. K. Singh, S. D. Solomon, H. Uno and M. A. Pfeffer: Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. *Circulation*, 124(25), 2903-8 (2011)
DOI: 10.1161/CIRCULATIONAHA.111.030411
 423. T. Frietsch, M. H. Maurer, J. Vogel, M. Gassmann, W. Kuschinsky and K. F. Waschke: Reduced cerebral blood flow but elevated cerebral glucose metabolic rate in erythropoietin overexpressing transgenic mice with excessive erythrocytosis. *J Cereb Blood Flow Metab*, 27(3), 469-76 (2007)
DOI: 10.1038/sj.jcbfm.9600360
 424. S. M. Bode-Boger, R. H. Boger, M. Kuhn, J. Radermacher and J. C. Frolich: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. *Kidney Int*, 50(4), 1255-61. (1996)
DOI: 10.1038/ki.1996.435
 425. T. De Palo, M. Giordano, F. Palumbo, R. Bellantuono, G. Messina, V. Colella and A. D. Caringella: Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. *Pediatr Nephrol*, 19(3), 337-40 (2004)
DOI: 10.1007/s00467-003-1364-1
 426. F. Semeraro, A. Cancarini, F. Morescalchi, M. R. Romano, R. dell'Omo, G. Ruggeri, L. Agnifili and C. Costagliola: Serum and intraocular

- concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. *Diabetes Metab*, 40(6), 445-51 (2014)
DOI: 10.1016/j.diabet.2014.04.005
427. O. O. Ogunshola, M. Moransard and M. Gassmann: Constitutive excessive erythrocytosis causes inflammation and increased vascular permeability in aged mouse brain. *Brain Res*, 1531, 48-57 (2013)
DOI: 10.1016/j.brainres.2013.07.033
428. Y. C. Shang, Z. Z. Chong, S. Wang and K. Maiese: WNT1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern beta-Amyloid Apoptotic Injury of Microglia. *Curr Neurovasc Res*, 9(4), 239-249 (2012)
DOI: 10.2174/156720212803530618
429. N. Shahani, W. Pryor, S. Swarnkar, N. Kholodilov, G. Thinakaran, R. E. Burke and S. Subramaniam: Rheb GTPase regulates beta-secretase levels and amyloid beta generation. *J Biol Chem*, 289(9), 5799-808 (2014)
DOI: 10.1074/jbc.M113.532713
430. T. Ma, C. A. Hoeffler, E. Capetillo-Zarate, F. Yu, H. Wong, M. T. Lin, D. Tampellini, E. Klann, R. D. Blitzer and G. K. Gouras: Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. *PLoS One*, 5(9) (2010)
DOI: 10.1371/journal.pone.0012845
431. T. Jiang, J. T. Yu, X. C. Zhu, M. S. Tan, H. F. Wang, L. Cao, Q. Q. Zhang, J. Q. Shi, L. Gao, H. Qin, Y. D. Zhang and L. Tan: Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. *Pharmacol Res*, 81C, 54-63 (2014)
DOI: 10.1016/j.phrs.2014.02.008

Key Words: Akt, AMPK, apoptosis, autophagy, erythropoietin, forkhead, FoxO, mTOR, oxidative stress, rapamycin, sirtuin, SIRT1, stem cells, trauma, WISP1, Wnt, Review

Send correspondence to: Kenneth Maiese, Cellular and Molecular Signaling, Newark, New Jersey 07101, E-mail: wntin75@yahoo.com